STK38L kinase ablation promotes loss of cell viability in a subset of KRAS-dependent pancreatic cancer Cell lines by Grant, Trevor James
Boston University
OpenBU http://open.bu.edu
Theses & Dissertations Boston University Theses & Dissertations
2017
STK38L kinase ablation promotes
loss of cell viability in a subset of
KRAS-dependent pancreatic cancer
Cell lines
https://hdl.handle.net/2144/26511
Boston University
BOSTON UNIVERSITY 
 
SCHOOL OF MEDICINE 
 
 
 
 
 
Dissertation 
 
 
 
 
 
STK38L KINASE ABLATION PROMOTES LOSS OF CELL VIABILITY IN A 
 
SUBSET OF KRAS-DEPENDENT PANCREATIC CANCER CELL LINES 
 
 
 
 
by 
 
 
 
 
TREVOR JAMES GRANT 
 
M.A., Boston University, 2010 
B.A., Boston University, 2010 
 
 
 
 
 
 
 
Submitted in partial fulfillment of the 
 
requirements for the degree of 
 
Doctor of Philosophy 
 
2017  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
© 2017 
 TREVOR JAMES GRANT 
 All rights reserved  
Approved by 
 
 
 
 
 
First Reader _________________________________________________________ 
 Anurag Singh, Ph.D. 
 Assistant Professor of Pharmacology and Medicine 
 
 
Second Reader _________________________________________________________ 
 Xaralabos Varelas, Ph.D. 
 Associate Professor of Biochemistry 
 
 
  
  iv
DEDICATION 
 
 
 
 
To my parents 
For their unconditional love and support 
  
  v
ACKNOWLEDGMENTS 
First and foremost, I would like to thank my mentor, Dr. Anurag Singh, for 
giving me the opportunity to work in his lab. My pursuit of a PhD stemmed from the 
desire to hone my critical thinking skills, expand my repertoire of experimental 
techniques, and learn how to independently spearhead a research project from start to 
finish. Anurag’s guidance and support have made that possible all of these things 
possible. I am a better scientist for having worked with him. 
I would also like to thank Dr. Anita Mehta for all her guidance and support over 
the past few years. Whether I needed advice regarding my research or a boost in morale, 
she was always incredibly helpful. Her insights on science and life outside of the lab have 
helped me to become not only a better scientist, but also a better person. I couldn’t ask 
for a better friend and colleague. 
I would like to express my appreciation and thanks to my fellow colleagues in the 
Shamim and Ashraf Dahod Breast Cancer Research Center. Working with all of them has 
been a truly incredible experience. The camaraderie that we have shared both inside and 
outside of the workplace is the thing that I will miss the most about my time as a graduate 
student. I would like to specifically acknowledge my fellow lab mates Will Whipple and 
Kevin Hua. It has been a privilege to work alongside such awesome individuals. Our 
interactions were one of the many things that made me look forward to coming into the 
lab every day. I would also like to acknowledge Sanghee Lim, who was a constant 
source of knowledge and advice. Our scientific discussions helped me to carefully 
evaluate and further develop my work. 
  vi
I would also like to thank the members of my dissertation advisory committee: 
Dr. Neil Ganem, Dr. Bob Varelas, Dr. Tom Gilmore, and Dr. Nabeel Bardeesy. Their 
guidance over the past few years has been instrumental in driving my research forward 
and helping me to develop as a scientist. Our meetings have been an invaluable learning 
experience. They have shown me the importance of evaluating scientific research from 
multiple perspectives and how working collaboratively can ultimately yield better results. 
Several members of the Pharmacology Department also deserve recognition for 
my success. I would like to thank Dr. David Farb and Dr. Carol Walsh for building 
such an excellent training program. Their desire to help students excel above all else is 
truly admirable and very much appreciated. I would also like to acknowledge Nadiyah 
Shaheed, Sara Johnson, Wanda Roberts, and Christina Cherel for all of their efforts 
behind the scenes. Their hard work has kept the Pharmacology Department running 
smoothly and enabled both students and faculty to stay focused on our research. 
I would like to thank my fellow classmates: Leah Ray, Dan Appico, and Neema 
Yazdani. I consider myself incredibly lucky to be part of such a supportive, hard-
working, and engaging group of people. It has been a true pleasure growing together as 
scientists. I know they will all do great things, and I wish them the best of luck in all their 
future endeavors. 
Last, but certainly not least, I would like to thank my family and friends for all of 
their support throughout this journey. I would not have made it to where I am today 
without them. In particular, I would like to acknowledge my mother. During my tenure as 
a graduate student, she was diagnosed with breast cancer and suffered the passing of my 
  vii
father. There were days when research was the furthest thing from my mind. 
Nevertheless, she insisted that I continue to work hard and put forth my best effort. Her 
resilience and constant encouragement gave me the strength to keep pushing forward. All 
that I have accomplished would not have been possible without her unwavering support, 
and I am eternally grateful for everything that she has done for me. 
  
  viii 
STK38L KINASE ABLATION PROMOTES LOSS OF CELL VIABILITY IN A 
SUBSET OF KRAS-DEPENDENT PANCREATIC CANCER CELL LINES 
TREVOR JAMES GRANT 
Boston University School of Medicine, 2017 
Major Professor: Anurag Singh, Ph.D., Assistant Professor of Pharmacology and 
Medicine 
 
ABSTRACT 
Pancreatic ductal adenocarcinomas (PDACs) are highly aggressive malignancies, 
associated with poor clinical prognosis and limited therapeutic options. The KRAS 
oncogene is mutated in over 90% of PDACs and plays a pivotal role in tumor 
progression. Global gene expression profiling of PDAC reveals 3-4 major molecular 
subtypes with distinct phenotypic traits and pharmacological vulnerabilities, including 
variations in oncogenic KRAS pathway dependencies. PDAC cell lines of the aberrantly 
differentiated endocrine exocrine (ADEX) subtype are robustly KRAS-dependent for 
survival. The KRAS gene is located on chromosome 12p11-12p12, a region amplified in 
5-10% of primary PDACs. Within this amplicon, we identified co-amplification of KRAS 
with the STK38L gene in a subset of primary human PDACs and PDAC cell lines. This 
provided rationale to determine whether PDAC cell lines are dependent on STK38L 
expression for proliferation and viability. STK38L (also known as NDR2) encodes a 
nuclear Dbf2-related (NDR) serine/threonine kinase, which shares homology with Hippo 
pathway LATS1/2 kinases. We show that STK38L expression levels are elevated in a 
subset of primary PDACs and PDAC cell lines that display ADEX subtype 
characteristics, including overexpression of mutant KRAS. RNAi-mediated depletion of 
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STK38L in a subset of ADEX subtype cell lines results in decreased cellular proliferation 
and increased apoptotic cell death. Concomitant with cytostatic and cytotoxic effects, 
STK38L depletion causes increased expression of the LATS2 kinase and the cell cycle 
regulator p21. LATS2 depletion partially rescues the cell proliferation and viability 
effects of STK38L depletion. Lastly, high STK38L mRNA expression is associated with 
worse patient prognosis compared to low STK38L expression in PDACs. Taken together, 
our study uncovers STK38L as a candidate, targetable vulnerability in a subset of 
molecularly defined PDACs. 
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CHAPTER I: INTRODUCTION 
A. The Molecular Pathogenesis of Pancreatic Cancer1 
1. Introduction 
 The pancreas is a glandular organ with both endocrine and exocrine function [1, 
2]. Its overall purpose is to maintain metabolic homeostasis by producing hormones that 
regulate blood glucose levels as well as enzymes that aid in digestion. The pancreas is 
derived from the embryonic foregut of the endodermal germ layer [3]. During embryonic 
development, two buds that ultimately give rise to the dorsal and ventral pancreas emerge 
from the foregut. As these buds expand, they are gradually repositioned over time until 
they come into contact and fuse together, forming the mature pancreas. Under the control 
of various developmental cues, pancreatic progenitor cells become acinar, endocrine, or 
ductal in function. Endocrine cells (α, β, and δ) secrete hormones like insulin, glucagon, 
and somatostatin into the circulatory system to modulate blood glucose levels [1]. This 
homeostatic function ensures that the metabolic demands of various tissues and organs 
are met. Acinar cells in the ducts secrete enzymes like trypsinogen, chymotrypsinogen, 
lipase, and amylase into the pancreatic duct [2]. These enzymes subsequently enter into 
the small intestine, where they aid in the digestion of various dietary macromolecules 
such as proteins, carbohydrates, and lipids. 
 Pancreatic dysfunction can lead to a number of common diseases including 
diabetes, pancreatitis, and cancer [4-6]. Diabetes is the most prevalent of these diseases. 
                                                        
1 Reprinted from Progress in Molecular Biology and Translational Science, Vol. 144. T.J. Grant, K. Hua, 
and A. Singh. Molecular Pathogenesis of Pancreatic Cancer, Pages No. 241-275, Copyright 2016, with 
permission from Elsevier. 
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However, cancer of the pancreas is by far the deadliest, and its etiology is often linked to 
other pancreatic disorders, including diabetes. Pancreatic cancer is the fourth leading 
cause of cancer related deaths in the United States and is associated with a particularly 
poor prognosis [7]. Patients diagnosed with this disease exhibit a median overall survival 
of less than six months and a five-year survival rate of roughly 8%. The poor prognosis 
associated with pancreatic cancer is attributed in part to poor methods of early detection 
[8]. Patients often remain asymptomatic until the disease has disseminated throughout the 
body. Additionally, the therapeutics used to treat pancreatic cancer are relatively 
ineffective, as they fail to extend patient survival more than several months [9]. 
Overcoming these challenges will be critical in the future treatment of the disease, as it is 
expected to become the second leading cause of cancer related deaths in the United States 
by 2030 [10]. 
 Pancreatic cancers can arise from either endocrine or exocrine cells. Thus, 
endocrine and exocrine tumors can be distinguished by histological appearance. 
Endocrine tumors are relatively uncommon, and constitute less than 5% of all pancreatic 
cancers. They are associated with a median survival of 27 months and a 0.28-fold lower 
risk of mortality in comparison to the much more common pancreatic adenocarcinoma 
[11]. Endocrine tumors are commonly derived from pancreatic islet cells, and often 
produce constitutively high levels of pancreatic hormones. They can be further 
categorized into insulinomas, glucagonomas, and gastrinomas depending on their cell of 
origin and the hormones that they secrete. Pancreatic endocrine tumors can be readily 
diagnosed due to their excessive hormone secretion, which leads to dramatic symptoms 
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such as hypoglycemia or necrolytic migratory erythema (skin rash) [12]. Pancreatic 
cancers derived from exocrine cells are much more common than endocrine tumors and 
can typically be classified into two histological subtypes. The pancreatic ductal 
adenocarcinoma (PDAC) subtype accounts for the majority of exocrine tumors and 
constitutes more than 90% of all pancreatic malignancies. PDACs are derived from 
epithelial cells that line the pancreatic duct and appear gland-like due to their origin [11]. 
These cancers frequently metastasize to the liver or lymph nodes [13]. Due to their lack 
of symptoms at the early stages of cancer development, PDACs are often diagnosed at a 
late stage, potentially after the cancer has already metastasized. As a result, anticancer 
therapeutics tend to be weakly effective due to the cancers having acquired strong 
cytoprotective mechanisms that promote drug resistance. Because of this aggressiveness 
and drug resistance, estimated median survival for PDAC can be as short as 4 months 
[11]. 
 PDACs are preceded by the development of hyperplastic lesions known as 
pancreatic intraepithelial neoplasias (PanINs) and intraductal papillary mucinous 
neoplasms (IPMNs) that are precancerous and exhibit a propensity to develop into cancer 
(Fig. 1). IPMNs look like papillae (finger-like structures) that protrude into the pancreatic 
duct [14]. Mucinous tumors are the second most common histological subtype of 
pancreatic cancer, constituting less than 10% of cases. These tumors are usually much 
less invasive than adenocarcinomas at the time of diagnosis and have a 0.88-fold lower 
risk of mortality by comparison [11]. Mucinous tumors also originate from the pancreatic 
ductal epithelium, but secrete mucin, which can be seen in and around the cells, causing 
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them to appear like they are ‘floating’ [15, 16]. There are many other subtypes of 
pancreatic cancer, such as those that arise from acinar cells, which are undifferentiated 
and resemble liver cancers. However, these subtypes are rare and will not be discussed in 
this chapter. 
 
Figure 1. Disease Progression Model of Pancreatic Cancer. Pancreatic cancer arises from two 
histological types of precursor lesions: PanINs and IPMNs. Through progressive stages of pathogenesis, 
molecular changes occur, leading to increasing degrees of nuclear and cytoskeletal abnormalities. Genetic 
alterations commonly observed in these lesions are indicated with respect to the stages in which they most 
often occur. 
 This chapter will focus on the molecular etiology of PDAC, the most prevalent 
form of pancreatic malignancy. The core genetic alterations that contribute to PDAC 
pathogenesis will be discussed. Furthermore, the molecular subtypes of PDAC will be 
presented with a focus on their cellular origin and the genetic alterations associated with 
them. The diverse and deregulated signaling pathways that contribute to PDAC 
pathogenesis will also be described in detail. To conclude, the molecular characteristics 
of PDAC will be discussed in relation to the current therapeutic strategies employed to 
manage the disease in the clinic and future approaches that may further improve patient 
prognosis. 
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2. Genetic Alterations in Pancreatic Cancer 
 Whole exome-sequencing studies have revealed that PDAC is a molecularly 
heterogeneous disease characterized by four common genetic alterations: oncogenic 
KRAS mutation and inactivation of the tumor suppressors CDKN2A, TP53, and SMAD4 
(Fig. 1, 2A) [6]. However, myriad additional genes are mutated in subsets of tumors, 
typically at a very low frequency (≤10%), with many of these mutations not occurring in 
a recurrent manner. Further analysis of these infrequent alterations has revealed that they 
converge on a relatively small number of pathways and cellular processes including 
KRAS, TGF-β, WNT, NOTCH, and Hedgehog signaling as well as S-phase entry, axonal 
guidance, chromatin remodeling, DNA repair, and RNA processing [17, 18]. 
Understanding how context-dependent interactions between these various genetically 
altered pathways contribute to PDAC progression is a key goal in the development of 
more selective and efficacious therapeutic modalities to treat the disease. 
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Figure 2. Deregulated Signaling Networks in Pancreatic Cancer. A. RTK and cell cycle-regulatory 
signaling networks frequently altered in pancreatic cancer. Oncogenes exhibiting gain-of-function 
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mutations are indicated by a dark dashed line. Tumor suppressor genes altered in the disease are indicated 
by a lighter dashed line. The frequencies at which these genes are altered are also included. Oncogenic 
KRAS mutation cooperates with the loss of various tumor suppressor genes to promote cellular 
proliferation, growth, survival, and stem cell renewal. B. Hippo signaling is frequently deregulated in 
pancreatic cancer. The ability of the pathway to restrict cell growth and induce apoptosis is mediated by a 
number of stimuli including cell density, glucose levels, serum levels, and cytoskeletal tension. 
 
a. Oncogenic KRAS Mutations 
 Activating KRAS mutations are the defining genetic feature of PDAC progression 
and are found in approximately 92% of PDAC [18]. KRAS, a member of the RAS 
superfamily, encodes a small GTPase that regulates diverse cellular processes including 
cell proliferation, differentiation, survival, and migration (Fig. 2A) [19]. Under normal 
physiological conditions, KRAS cycles through a GTP-bound active state and a GDP-
bound inactive state. The transition between these two states is modulated by guanine 
nucleotide exchange factors (GEFs; e.g. Sos1), which catalyze the exchange of GDP for 
GTP, and GTPase-activating proteins (GAPs; e.g. NF1), which enhance the intrinsically 
weak ability of KRAS to hydrolyze GTP [20, 21]. In quiescent cells, KRAS is 
predominantly GDP-bound. However, upon growth factor stimulation, GEFs are able to 
bind to KRAS and promote its activation by catalyzing GDP-GTP exchange. In many 
solid cancers, KRAS or one of its closely related family members (HRAS and NRAS) 
undergo mutations that ultimately impair their ability to hydrolyze GTP. HRAS and NRAS 
mutations are typically not found in PDAC.  Oncogenic RAS proteins are locked in an 
active state that results in constitutive stimulation of effector pathways capable of driving 
tumor development [22]. The major effector pathways downstream of active RAS are 
those mediated by RAF/MEK/ERK, PI3K and RAL-GEF. 
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 KRAS point mutations typically result in a single amino acid substitution at one of 
three codons: G12, G13, or Q61 [21]. All three substitutions occur in the catalytic domain 
of the GTPase. G12 and G13 mutations introduce a steric hindrance that blocks the 
formation of van der Waals interactions between KRAS and GAPs[23].  Q61 mutations 
disrupt the coordination of a water molecule required for GTP hydrolysis [24]. Although 
all three mutations promote KRAS activation by impairing its GTPase activity, the 
frequencies at which they occur are vastly disparate. Substitutions at codon G12 
(typically G12D or G12V) are the most prevalent (82%) followed by Q61 (14%) and G13 
(<1%) [21]. Interestingly, the three common KRAS mutant alleles exhibit contrasting 
functional properties. Tumors harboring KRAS Q61 substitutions display reduced MAPK 
activity and are associated with a better prognosis than substitutions at other codons [25]. 
This suggests that different KRAS mutations promote tumorigenesis in distinct ways. 
 Activating KRAS mutations are the earliest genetic alteration in the development 
of almost all PDACs (Fig. 1), as they are prevalent in greater than 90% of low-grade 
precursor pancreatic intraepithelial neoplasia (PanIN) lesions [26]. PDAC is preceded by 
the emergence of PanIN lesions, which are classified into three stages (I-III) based on the 
degree of architectural disorganization and nuclear abnormalities of the tissue [6]. In vivo 
studies of genetically engineered mouse (GEM) models have demonstrated that PanINs 
readily develop as a consequence of KRAS-activating mutations but do not ultimately 
give rise to PDAC. Rather, the subsequent and combined inactivation of multiple tumor 
suppressor genes (i.e. CDK2NA, TP53, and SMAD4) is also required for malignant tumor 
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progression [6, 27, 28]. These findings suggest that KRAS mutations alone are not 
sufficient to promote PDAC progression. 
 Although oncogenic KRAS promotes the initiation of PDAC development, its 
role in tumor maintenance is less clear. In a GEM PDAC model, pancreas-specific 
induction of KRASG12D expression coupled with loss of a single TP53 allele results in the 
dedifferentiation of normal epithelial cells and the development of PanINs [29]. 
Extinction of oncogenic KRAS leads to the regression of these lesions, suggesting that it 
is required for PanIN progression. In a subsequent study, pancreas-specific induction of 
KRASG12D expression coupled with the loss of one or both TP53 alleles led to the 
development of PDAC [30]. Similar to the effects observed in PanINs, extinction of 
oncogenic KRAS in these PDAC lesions led to robust tumor regression. Taken together 
these studies suggest that oncogenic KRAS plays an essential role in both tumor initiation 
and maintenance. 
 In contrast to observations using GEMMs, which bear similarities to subsets of 
human PDAC, alternative studies using human PDAC-derived cancer cell lines suggest 
that KRAS is dispensable in certain contexts [31, 32]. Approximately half of human-
derived PDAC cell lines readily undergo apoptosis following RNAi-mediated depletion 
of the GTPase, indicating a state of KRAS oncogene “dependency.” The discrepancy 
between these findings and those obtained in the GEMM studies may be attributed to a 
number of factors. First, pharmacological vulnerabilities in GEMMs do not often 
translate to clinical trials of human cancers, as has been observed with inhibitors of the 
MAPK and PI3K pathways [20]. This suggests that, although the same defined genetic 
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mutations from human PDAC promote disease development in GEMMs, the resulting 
tumors likely display altered molecular characteristics compared to their human 
counterparts. Another potential explanation for the discrepancy between mouse and 
human cell line models is that some GEMM-derived tumors may be transiently 
dependent on KRAS during early stages of PDAC progression. In mouse xenografts, 
MAPK, PI3K, and RalGEF are all required for tumor initiation [33]. However, only the 
PI3K pathway is necessary for tumor maintenance, suggesting a reduced need for 
oncogenic KRAS. Furthermore, activation of PI3K/AKT signaling by the tumor 
microenvironment is able to rescue the loss of mutant KRAS. This suggests that KRAS 
may become dispensable in the later stages of PDAC progression if the PI3K pathway is 
activated. Such a context may be difficult to model in GEMMs due to the rapid disease 
onset that results in a severe “dependency” on mutant KRAS for tumor maintenance.  
 More recent studies in GEMMs have demonstrated that the need for KRAS can be 
bypassed by enhanced mitochondrial activity or Hippo pathway deregulation [34-36]. In 
both cases, depletion of the KRAS protein resulted in robust tumor regression, consistent 
with previous in vivo work. However, subpopulations of cells were able to drive tumor 
relapse. In the case of Hippo pathway deregulation, surviving cells expressed lower 
KRAS protein levels and were unresponsive to KRAS depletion. Furthermore, the 
relapsed tumors exhibited a more mesenchymal morphology, reminiscent of the 
phenotype observed in PDAC cell lines that were insensitive to KRAS depletion [31]. 
Similarly, surviving cells that bypassed KRAS dependence by increased oxidative 
phosphorylation were also more stem-like in morphology. Taken together, these studies 
  
11
demonstrate that KRAS may be dispensable in subsets of tumors or subsets of cells 
within a tumor that can bypass the dependence on oncogenic KRAS signaling. As 
discussed below, this poses a new challenge to developing effective therapies to treat 
PDAC by targeting KRAS or its downstream effectors. 
 
b. Tumor Suppressor Genes 
 Tumor suppressor genes (TSGs) restrict cell proliferation in the presence of 
oncogenic driver mutations by inducing cell cycle arrest, apoptosis, or senescence. 
Hence, the functional inactivation of TSGs is essential for tumorigenesis [37]. A number 
of TSGs are functionally lost in PDAC, the three most common of which are CDKN2A, 
TP53, and SMAD4/DPC4 [6]. The inactivation of these genes occurs in a sequential 
manner following the appearance of oncogenic KRAS mutation in concordance with the 
multi-stage carcinogenesis model proposed by Vogelstein and colleagues (Fig. 1) [38]. 
Together, TSG alterations constitute a major driving force of PDAC development.  
 CDKN2A encodes the p16/INK4A protein, a cyclin-dependent kinase inhibitor 
responsible for blocking entry into S-phase of the cell cycle [39]. It is the earliest and 
most frequently altered TSG observed in PDAC. Approximately 95% of tumors exhibit 
functional loss of this gene as a consequence of intragenic mutation coupled with loss of 
the second allele (40%), homozygous deletion (40%), or promoter hypermethylation 
(15%) [40, 41]. CDKN2A inactivation is typically detected in moderately advanced 
PanINs, prior to the development of PDAC[42]. CDKN2A loss is crucial in disease 
pathogenesis, as p16 induces senescence following the introduction of oncogenic KRAS 
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[43]. For this reason, CDKN2A inactivation occurs immediately following the appearance 
of activating KRAS mutations and at a similar frequency to bypass the senescence 
response. 
 The CDKN2A locus also encodes the tumor suppressor ARF/p14, which is 
expressed via a distinct first exon that introduces an alternate reading frame in 
downstream exons shared with CDKN2A/p16 [39]. The ARF/p14 protein induces growth 
arrest or apoptosis by inhibiting MDM2-dependent p53 proteolysis. However, the 
frequent inactivation of p53 in PDAC, which often occurs concomitantly with p14 loss, 
suggests that this mechanism may not be relevant to disease progression. Furthermore, 
p14 inactivation only occurs as a consequence of CDKN2A deletion (40%) [40, 41]. 
Expression of this tumor suppressor is driven by an independent promoter that is 
unaffected by epigenetic changes influencing p16 transcription. Additionally, p14 
appears to be spared by p16-inactivating mutations. These discrepancies indicate that loss 
of p16 is more critical in disease pathogenesis and that p14 loss is a byproduct. However, 
p14 may hinder the development of PDAC via p53-independent mechanisms, as it has 
been shown to repress ribosomal RNA processing, NF-κB transactivation, and c-Myc 
induced hyperproliferation [44-46]. Furthermore, p14 can promote cell death by 
enhancing c-Myc-induced apoptosis as well proteasome-dependent degradation of the 
antiapoptotic transcriptional corepressor C-terminal binding proteins 1 and 2 (CtBP1/2) 
[46, 47]. Thus, p14 may hinder PDAC development via multiple mechanisms in specific 
contexts. 
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 Another major TSG in PDAC is TP53, which encodes the transcription factor 
p53. Functional loss of this gene has been observed in up to 75% of tumors as a 
consequence of missense mutation and loss of heterozygosity (LOH) [40, 48]. Amino 
acid substitutions impair the ability of p53 to bind DNA, thus ablating its function as a 
transcription factor. As a consequence, mutant p53 is unable to induce the expression of 
genes that promote cell cycle arrest or apoptosis (e.g. CDKN1A/p21, BAX, NOXA, and 
PUMA) in response to cellular stress or DNA damage [49]. Inactivation of p53 is 
typically observed in advanced PanINs following the loss of CDKN2A [43]. At this stage 
of disease progression, the accumulation of DNA damage is believed to induce a 
selective pressure that necessitates the loss of p53 activity for the continued survival and 
proliferation of tumorigenic cells. 
 Emerging evidence suggests that TP53 mutations in PDAC may also contribute to 
the highly metastatic nature of the disease, thus defining a gain of function role for 
mutant p53 [50]. In one study, a specific tumor-associated mutant form of p53 (p53R175H) 
was shown to bind the protein p73 and impair its ability to repress the expression of 
platelet-derived growth factor receptor β (PDGFRβ) [51]. The resulting upregulation of 
PDGFR expression promotes an autocrine signaling loop that enhances the motility, 
invasiveness, and metastatic potential of tumor cells in mice. Additional studies have 
demonstrated that inactivation of p53 in other cancer types also promotes metastasis by 
rendering the transcription factor incapable of inducing the expression of genes that 
counteract cell migration, epithelial-mesenchymal transition (EMT), and stemness [52, 
53]. Thus, mutation of p53 may promote metastasis in PDAC via PDGFR-independent 
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mechanisms. Collectively, these studies highlight the complexity of genetic alterations in 
PDAC, as p53 functions as both a tumor suppressor and an enhancer of metastasis. 
 The low-frequency inactivation (<10%) of several additional TSGs has been 
observed in PDAC [54]. The most notable of these genes, STK11/LKB1, encodes a 
serine/threonine (S/T) kinase that regulates cell polarity and metabolism [55]. Loss of 
LKB1 as a consequence of germline mutation is most frequently associated with Peutz-
Jeghers syndrome (PJS), a disease characterized by the development of benign polyps in 
the gastrointestinal tract. Individuals with PJS have a 93% cumulative lifetime risk of 
developing other malignancies, the most frequent of which is PDAC (36% lifetime risk) 
[56]. As both germline and somatic/sporadic LKB1 mutations are found at low frequency 
in PDAC, LKB1 may play an important, context-specific role in disease pathogenesis 
[57]. One such context may be in the absence of p53 mutation, where LKB1 
haploinsufficiency was shown to cooperate with KRASG12D in a GEM model to 
accelerate PDAC development by suppressing p21-dependent cell cycle arrest [58]. This 
limited but critical role highlights the potential importance of low frequency genetic 
alterations in subsets of PDAC. 
 Several caretaker genes, which have tumor suppressor function, are also 
functionally lost in subsets of PDAC. Unlike CDKN2A and TP53, which are considered 
classical TSGs, caretaker genes do not directly regulate proliferation. Rather, their 
function is to maintain the integrity of the genome, preventing the accumulation of 
mutations that might otherwise promote tumor development. A number of caretaker 
genes are lost in PDAC including BRCA1, BRCA2, hMLH1, and hMSH2 [6, 54]. Similar 
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to LKB1, inactivation of these TSGs can occur as a consequence of germline or somatic 
mutation and is more commonly associated with other malignancies. However, they play 
an implicit role in disease pathogenesis. 
 
c. TGF-β/SMAD4 Alterations 
 Alterations in the transforming growth factor-β (TGF-β) signaling pathway play 
context-dependent roles in PDAC pathogenesis, as the pathway can both induce apoptosis 
in some contexts and/or promote invasion and metastasis in others. The antiproliferative 
effect of TGF-β signaling depends on the activity of the transcriptional co-activator 
SMAD4/DPC4. SMAD4 mutations and homozygous deletions lead to accelerated tumor 
development in a KRASG12D GEM model of PDAC [28]. SMAD4 reintroduction in 
SMAD4-deficient GEMM-derived tumor cells results in apoptosis upon treatment with 
TGF-β, highlighting its tumor suppressive properties. Approximately 90% of PDAC 
cases exhibit loss of heterozygosity (LOH) for the SMAD4 locus [59]. Furthermore, 
SMAD4 biallelic inactivation has been observed in roughly 50% of tumors as a 
consequence of homozygous deletion or intragenic mutations [60]. These genetic 
alterations typically occur in advanced PanINs following the loss of CDKN2A, making 
SMAD4 loss one of the final steps in tumor initiation [43, 61]. Interestingly, SMAD4 loss 
predicts poorer patient prognosis compared to tumors with intact, wild-type SMAD4 
expression [62]. 
 TGF-β is a known inducer of the developmental epithelial-to-mesenchymal 
transition (EMT) program, discussed in detail below. Upon EMT induction, TGF-β can 
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also promote the activation of an apoptotic program, which is referred to as “lethal 
EMT.” It has recently been postulated that the tumor suppressor function of Smad4 in 
PDAC can be attributed to its involvement in the induction of lethal EMT [63]. In 
canonical TGF-β signaling, the TGF-β ligand binds to its receptor (TGFBR), resulting in 
activation of Smad2/3, which subsequently bind to Smad4. The resulting protein complex 
translocates to the nucleus and induces a Smad4-dependent transcriptional program that 
promotes EMT. As a consequence of this program, expression of the gastrointestinal-
lineage master regulator Klf5 is repressed. Klf5 can cooperate with Sox4 to promote 
PDAC progression. However, loss of Klf5 expression dramatically alters the role of Sox4 
to that of an apoptosis-inducer. This mechanism highlights the complex role of Smad4 in 
context-dependent tumor suppression by the TGF-β pathway in the pathogenesis of 
PDAC. 
 Although TGF-β signaling clearly plays a role in tumor suppression, the pathway 
can also drive invasion and metastasis. At present, the underlying mechanism behind this 
alternative role is unclear. It has been suggested that TGF-β promotes invasion and 
metastasis via the induction of EMT [64]. However, more recent work in lung and 
pancreatic cancers has demonstrated that EMT is dispensable for metastasis [65, 66]. 
These conflicting studies highlight the need to better understand how TGF-β signaling 
contributes to PDAC progression. EMT is clearly an important phenotypic outcome of 
TGF-β mediated tumorigenic processes, as it can induce stemness and drug resistance 
[67]. However, other mechanisms downstream of TGF-β are likely to be involved in 
PDAC progression, including activation of the TGF-β activated kinase (TAK1), which 
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activates antiapoptotic signaling mechanisms [68]. Low-frequency mutations have been 
observed in the TGFBR1 and TGFBR2 TGF-β receptor subunits [69]. However, like 
SMAD4 inactivation, these alterations are most likely the result of a selective pressure to 
eliminate the tumor suppressor function of the pathway. Thus, the pro-metastatic 
functions of TGF-β remain intact in the vast majority of PDAC. Ultimately, these 
observations suggest that the TGF-β pathway is critical for PDAC pathogenesis, playing 
complex and context-dependent roles in disease progression. 
 
d. Telomere Abnormalities 
 Telomeres are specialized nucleoprotein structures that maintain the integrity of 
the genome by protecting the ends of linear chromosomes. These structures gradually 
shorten, or erode, over time with each successive round of cell division due to inefficient 
telomere-directed replication. When telomeres become critically short, sister chromatids 
can fuse together at their ends, forming a bridge [70, 71]. This linkage poses a problem 
during anaphase, as the chromatids are unable to properly separate. Thus, when fused 
sister chromatids break during segregation in mitosis, the gain or loss of chromosomal 
fragments can occur [72, 73]. This break-fusion-bridge (BFB) process occurs in a cyclical 
manner, promoting genomic instability and a selective pressure to eliminate antiapoptotic 
pathways. 
 Telomere erosion has been observed in more than 90% of low-grade PanINs, 
suggesting that it is an early event in PDAC pathogenesis [74]. This genomic alteration 
would typically result in p53-induced senescence [75]. However, the frequent 
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inactivation of p53 sustains continued tumor cell proliferation [76]. Robust telomere 
shortening precedes the loss of p53 and likely contributes to the selective pressure that 
results in its loss. Although telomeric loss can promote a genomically unstable state 
conducive to tumor formation, it may also be detrimental to disease progression if left 
unchecked, as the reactivation of telomerase has been observed in invasive PDAC [77]. 
This reactivation most likely occurs to prevent additional genomic alterations that would 
be catastrophic. Telomerase reactivation can promote tumor progression via induction of 
cellular immortalization, allowing for sustained telomere elongation during repeated 
rounds of DNA replication. 
 
3. Deregulated EMT in Pancreatic Cancer 
 Epithelial cells are located at the surface of many tissues and organs that are 
derived from the endodermal and ectodermal embryonic germ layers. These cells form 
sheets that act as barriers against xenobiotic and pathogenic agents and serve specialized 
secretory functions in the intestine and the pancreas. Due to their location and function, 
epithelial cells exhibit a distinct apical-basolateral polarity created by macromolecular 
protein complexes at cell-cell contacts known as adherens and tight junctions. In contrast 
to epithelial cells, mesenchymal cells serve in anchoring or scaffolding roles and 
participate in early embryonic development, wound healing, and tissue repair. 
Mesenchymal cells lose apical-basolateral polarity as a consequence of the EMT 
transcriptional program. EMT is a developmental process in which the adherens and tight 
junctions of epithelial cells are degraded, resulting in a loss of cellular polarity and 
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conversion to mesenchymal cells that are highly motile and invasive [78]. The key 
molecular changes associated with EMT are loss of epithelial protein marker expression, 
such as the adherens junction component E-cadherin, and gain of mesenchymal marker 
expression, including vimentin. During embryonic development, these cells can travel to 
distant sites and differentiate back into epithelial cells, known as mesenchymal-to-
epithelial transition (MET), enabling tissue morphogenesis, tissue repair, and wound 
healing. EMT is a transcriptional program regulated by specific extracellular factors and 
cytokines, including TGF-β, Wnt, and Notch, resulting in the activation of signaling 
pathways such as NF-κB. Many of these factors and pathways are all commonly 
dysregulated in cancer [79].  Of note, cells within tumors displaying EMT properties 
have been identified using immunohistological (IHC) methods. Many parallels can be 
drawn between the processes of wound healing and tumorigenesis, since both involve the 
recruitment of mesenchymal stem cells and are associated with increased cellular 
invasiveness. It is believed that EMT is an important step in cancer invasion and 
metastasis, as cells exhibiting EMT-like characteristics are often observed at the invasive 
front of tumors [80]. 
 EMT-associated signaling networks promote activation of the transcriptional 
repressors Snail, Slug, Zeb1, Zeb2/SIP1, and Twist [81]. These factors bind to the 
promoter of E-cadherin and block transcription by promoting chromatin condensation via 
the activation of histone deacetylases and other corepressors. This results in the loss of 
adherens junctions as well as loss of cell polarity [67]. TGF-β is a cytokine that promotes 
EMT through its ability to drive Smad complex association with Zeb proteins, resulting 
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in repression of E-cadherin expression [82]. TGF-β-mediated induction of EMT is 
accompanied by apoptosis and growth arrest, known as lethal EMT (see above). TGF-β 
can also induce transient activation of the RAS and PI3K/AKT pathways, which can help 
to block the apoptotic effects of the cytokine and produce a stable mesenchymal 
phenotype in cells [83]. Smad4, an important co-factor in TGF-β signal transduction, 
functions as a tumor suppressor in pancreatic cancer by promoting lethal EMT upon 
TGF-β stimulation. 
 In pancreatic cancer, as well as other malignancies, cancer stem cells (CSC) are 
multipotent or pluripotent progenitor cells in the tumor. CSCs can be identified and 
distinguished by high expression of cell surface markers including CD133 and CD44, 
which are typically not expressed on bulk tumor cells. They can self-renew as well as 
divide asymmetrically to give rise to differentiated cells. These characteristics allow 
CSCs to initiate or regenerate a tumor. CSCs are thought to be derived from existing 
progenitor cells or dedifferentiated cells within a tumor [67]. EMT is known to promote 
CSC-like properties in pancreatic cancer by inducing a CD44high and CD24low cell surface 
marker expression profile characteristic of cancer stem cells [84]. This observation 
suggests EMT plays a direct causal role in the emergence of CSCs. However, the 
mechanistic basis for the association between EMT and CSC induction remains to be 
fully elucidated. 
 Mesenchymal-like properties can render pancreatic cancers more resistant to 
anticancer therapeutics, especially cytotoxic agents that induce apoptotic cell death. 
When comparing mesenchymal-like cells in pancreatic cancer to epithelial-like cells, 
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mesenchymal-like cells are more resistant to gemcitabine, 5-fluorouracil (5-FU), 
cisplatin, and epidermal growth factor receptor (EGFR) inhibitors as assessed by cellular 
growth and viability [85]. Furthermore, pancreatic cancer cells that are intrinsically 
resistant to gemcitabine express high levels of vimentin and low levels of E-cadherin, 
indicating that these drug resistant cells are more mesenchymal in nature [86]. As EMT 
has been associated with the emergence of CSCs, it has been noted that the use of 
cytotoxic agents such as gemcitabine can lead to an enrichment of CD44high, CD24low 
CSC-like cells [84]. Finally, EMT is also associated with resistance to adjuvant or 
neoadjuvant radiotherapy, as resistant cells express high levels of vimentin and low levels 
of E-cadherin. These drug-resistant cells express high levels of the stem cell markers 
Oct4, CD24, and CD133, further indicating that EMT is associated with the acquisition of 
stem-like properties [87]. In the context of oncogenic KRAS signaling, studies indicate 
that loss of dependence on oncogenic KRAS for survival significantly correlates with 
mesenchymal-like phenotypic characteristics in PDAC cell lines [31]. These studies are 
supported by findings that primary PDAC tumors can be classified into distinct molecular 
subtypes based on the expression of EMT markers. These subtypes have been designated 
classical, exocrine-like and quasi-mesenchymal. Of note, the cell lines with quasi-
mesenchymal properties are weakly dependent on oncogenic KRAS to maintain viability 
[32]. 
 The clinical and pathophysiological significance of EMT in promoting metastasis 
and drug resistance remains controversial. A recent study has sought to tackle this 
question using EMT lineage tracing experiments in a spontaneous breast-to-lung 
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metastasis model [65]. The study demonstrates that a small proportion of cells in primary 
tumors undergo EMT and that cells found in lung metastases are predominantly 
epithelial-like. Furthermore, blocking the EMT process via the overexpression of miR-
200, a negative regulator of Zeb1, does not significantly impair the formation of distant 
lung metastases. These findings strongly suggest that EMT is not necessary for metastasis 
to occur efficiently. Using the same experimental conditions, the study also demonstrated 
that treatment of primary tumors with the chemotherapeutic agent cyclophosphamide 
results in the accumulation of mesenchymal-like cells which contribute more 
significantly to metastasis formation. Overexpression of miR-200 blocked this metastatic 
growth. Therefore, while EMT may not be required for metastasis under treatment naïve 
conditions, drug resistant cells with EMT-like properties may emerge with an increased 
metastasis-forming ability. Such studies will be critical in addressing the key roles of 
EMT in driving cancer metastasis and drug resistance across a number of cancer types, 
including pancreatic cancer. Importantly, associations between the EMT program, the 
emergence of CSCs, cancer invasiveness, KRAS dependence, and drug resistance 
provide new therapeutic opportunities for pancreatic cancer treatment. 
 
4. Molecular Subtype Classifications of Pancreatic Cancer 
 PDACs harbor a number of recurrent genetic alterations, including activation of 
KRAS in addition to loss of TP53, SMAD4, and CDKN2A [6]. A multitude of other 
mutations occur to varying degrees in subsets of tumors, leading to dysregulation of 
cellular processes such as DNA damage repair, cell cycle regulation, TGF-β signaling, 
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and chromatin modification [18]. However, some of the observed alterations may be 
“passenger” mutations that play minor roles in disease pathogenesis. Efforts to identify 
strategies to manage PDAC have been confounded by the molecular diversity of these 
aggressive tumors. Understanding the genetic variation in PDAC is now a major area of 
focus to develop more effective therapeutics. Although there are recurrent gene 
mutations, the transcriptional networks that are activated in tumors with similar genetic 
profiles can vary significantly as determined by global gene expression profiling. Using 
transcriptome data from RNA-seq analyses of primary PDACs, a recent study has 
generated a PDAC classification system of four major molecular subtypes. These are 
squamous (quasimesenchymal), pancreatic progenitor (classical), immunogenic, and 
aberrantly differentiated endocrine-exocrine (ADEX, exocrine-like) [18, 32]. Of note, 
these subtypes recapitulate the major subtypes identified by Collison and colleagues, 
including those associated with EMT [32]. 
 The squamous PDAC subtype is characterized by high mesenchymal marker gene 
expression and has the worst prognosis in comparison to the other subtypes. This subtype 
primarily comprises PDACs that are histologically identified as adenosquamous 
carcinoma [18, 32]. Squamous subtype tumors are enriched for TP53 mutations. They 
display activation of the p53 family member TP63ΔN and its associated transcriptional 
network. TP63ΔN regulates squamous epithelial cellular differentiation in contrast to 
columnar differentiation that is characteristic of pancreatic ductal epithelial cells. Thus 
squamous transdifferentiation in this molecular subtype is driven by an EMT-like 
program. Hypermethylation of pancreatic endodermal cell-fate determination genes, 
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including PDX1, GATA6 and HNF1B, further contributes to the dedifferentiated and 
mesenchymal nature of these tumors. A number of other phenotypic characteristics can 
distinguish squamous subtype PDAC tumors including increased prevalence KDM6A 
mutations, which affect chromatin remodeling, inflammation, the hypoxia response, 
metabolic reprogramming, TGF-β signaling, MYC activation, and autophagy. Finally, 
cell lines derived from squamous subtype tumors are more sensitive to the cytotoxic 
effects of gemcitabine [32].  
 Pancreatic progenitor subtype tumors are typically more epithelial-like in nature, 
as determined by high expression levels of epithelial marker genes, including adhesion-
associated genes such as CDH1/E-cadherin [18]. This subtype bears molecular 
similarities to KRAS-dependent PDAC cell lines [31]. Furthermore, high expression 
levels of genes that contribute to early pancreatic development are prevalent (FOXA2/3, 
PDX2, MNX1, and GATA6). These genes are important for terminal differentiation to 
pancreatic ductal epithelial cells. For example, PDX2 induces differentiation of ductal, 
exocrine, and endocrine cells of the pancreas. Cellular processes that are characteristic of 
the pancreatic progenitor subtype are fatty acid oxidation, steroid hormone biosynthesis, 
drug metabolism, and O-linked glycosylation of mucins. In contrast to the squamous 
subtype, pancreatic progenitor subtype tumor-derived cell lines are more sensitive to the 
EGFR inhibitor erlotinib [32]. Interestingly, development of pancreatic progenitor 
subtype tumors is linked to maturity onset diabetes of the young (MODY) [18]. 
 The aberrantly differentiated endocrine-exocrine (ADEX) tumor subtype is 
characterized by the simultaneous expression of transcriptional programs observed in the 
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endocrine and exocrine pancreas. Both programs are typically activated in the later stages 
of normal organ development and differentiation in a mutually exclusive manner. Genes 
upregulated in ADEX tumors play a role in acinar and endocrine differentiation as well as 
regeneration and pancreatitis. Furthermore, a number of these genes are associated with 
KRAS activation. ADEX tumors comprise a subclass of the pancreatic progenitor tumor 
subtype and are histologically associated with rare acinar cell carcinomas [18, 32]. 
 Immunogenic subtype tumors exhibit many of the same molecular characteristics 
observed in the pancreatic progenitor subtype but can be distinguished by the 
upregulation of various immune-related transcriptional programs. These programs are 
associated with B- and T-cell receptor signaling, Toll-like receptor signaling, antigen 
presentation, and acquired immune suppression through immune checkpoint pathways 
such as CTLA4 and PD1. Additionally, immunogenic subtype tumors exhibit a notable 
increase in infiltrating B- and T-cells. Tumors of this subtype display histological 
characteristics observed in mucinous non-cystic (colloid) adenocarcinomas and IPMN-
derived carcinomas [18]. PDACs are generally non-responsive to new classes of anti-PD1 
immunomodulatory checkpoint inhibitors, such as pembrolizumab. However, tumors of 
the immunogenic PDAC subtype may be more responsive to these immune checkpoint 
blockers either alone or in combination with other chemotherapeutic agents [88].  
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5. Deregulated Signaling Networks in Pancreatic Cancer 
a. The EGFR-KRAS Network 
 Receptor tyrosine kinases (RTKs) are cell surface receptors for many growth 
factor ligands, including epidermal growth factor (EGF) [89]. RTK dysregulation plays a 
significant role in many cancers. Upon binding to a growth factor ligand, RTKs form 
homo- or heterodimers, bringing their intracellular kinase domains into close proximity. 
The intracellular receptor regions are transphosphorylated to create docking sites for 
SH2-domain containing adapter proteins and enzymes. This activates many downstream 
signaling cascades mediated by proteins including RAS and PI3K (Fig. 2A) [90]. While 
EGFR mutations are rare in pancreatic cancer, inhibition of receptor kinase activity with 
erlotinib is moderately effective for treating a subset of PDACs [89]. Since KRAS is so 
frequently mutated in pancreatic cancer, the activation of RAS-mediated signaling 
pathways is thought to be a major driver of disease pathogenesis. Other RAS isoform 
genes such as HRAS and NRAS are mutated infrequently in pancreatic cancer, suggesting 
that the KRAS locus provides a unique advantage in the context of PDAC pathogenesis. 
Although not mutated in PDAC, HRAS and NRAS proteins may participate in 
EGFR/KRAS signaling networks to promote tumorigenesis via protection against DNA 
damage-induced stress pathways [91]. As discussed above, KRAS mutations occur early 
in PanIN lesions. Given the high prevalence of KRAS mutations, it is not surprising that 
the KRAS oncoprotein is a potent driver of PDAC development [92]. 
 RAS GTPase-activating proteins (GAPs) catalyze the hydrolysis of GTP to GDP, 
resulting in the inactivation of RAS [20, 21]. Thus, GAPs, such as the NF1 gene product, 
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can serve as tumor suppressors, although they are not frequently mutated in PDAC. The 
GTP bound form of RAS undergoes a conformational change in which two “switch” 
regions (I and II) converge to form the effector binding domain. This domain forms 
biochemical interactions with effectors to either promote their allosteric activation or 
enable recruitment to the membrane, allowing for initiation of downstream signal 
transduction cascades. One of the most well studied classes of RAS effectors are RAF 
family serine/threonine (S/T) kinases, which initiate the MEK/ERK MAP kinase pathway 
through a cascade of sequential phosphorylation events [19]. This results in 
phosphorylation and nuclear localization of transcription factors, such as Elk-1, that drive 
cell proliferation, inflammatory signaling, differentiation, and cell survival. RAS can also 
activate the lipid kinase PI3K by associating with the p110 subunit of the PI3K complex. 
This complex is composed of a p110 catalytic subunit and a p85 regulatory subunit, 
which together regulate many key tumorigenic processes, including cell survival and 
proliferation. Activated RAS recruits PI3K to the plasma membrane and promotes its 
catalytic activity, which is to facilitate the conversion of the membrane phospholipid 
phosphatidylinositol-4,5-bisphosphate (PIP2) to phosphatidylinositol-3,4,5-triphosphate 
(PIP3). PIP3 serves as a binding site for proteins that contain a pleckstrin-homology (PH) 
domain. To inactivate the PI3K pathway, the lipid phosphatase PTEN hydrolyzes PIP3 to 
PIP2. PTEN is often dysregulated in late stages of pancreatic cancer resulting in 
hyperactivation of the PI3K pathway and an acceleration of PDAC development [93]. A 
primary effector of PI3K activation is the AKT S/T kinase, which is activated by 
sequential phosphorylation mediated by PDK1 and mTORC2. AKT suppresses apoptosis 
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by promoting MDM2-dependent p53 proteolysis. It can also activate mTORC1, which 
phosphorylates 4EBP1 and ribosomal S6 kinase to promote CAP-dependent mRNA 
translation (Fig. 2A). The activation of mTORC1 is a key feature of many PDACs that 
results in increased protein translation, stem cell renewal, proliferation, and inhibition of 
autophagy via ULK1 kinase activation [94, 95]. 
 
b. Hippo Signaling 
 The Hippo tumor suppressor pathway regulates organ size and maintains tissue 
homeostasis by restricting cell proliferation and, when necessary, inducing apoptosis 
[96]. The Hippo pathway is activated by a kinase cascade that was originally discovered 
via genetic screens aimed at identifying tumor suppressor genes in the fruit fly 
Drosophila melanogaster. Mutations in various Hippo pathway component genes, such 
as Hippo (Hpo) itself, Salvador (Sav), and Warts (Wts) results in increased organ size as 
well as tissue overgrowth. The evolutionary conservation of Hippo signaling has been 
established in mammals, where pathway deregulation is frequently observed in many 
solid cancers, including PDAC [97, 98]. 
 The induction of Hippo signaling occurs in response to a number of stimuli 
including contact inhibition, serum deprivation, energy stress, and actin depolymerization 
(Figure 2B) [99]. These signals ultimately result in the phosphorylation and activation of 
large tumor suppressor kinases 1/2 (LATS1/2; Wts orthologs) by the MST1/2 (Hpo 
orthologs) kinases. Once activated, LATS1/2 phosphorylate the transcriptional co-
activator Yes-associated protein (YAP) and its vertebrate-specific paralog transcriptional 
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co-activator TAZ, encoded by the WWTR1 gene. Phosphorylation of YAP and TAZ 
promotes their association with 14-3-3 proteins, resulting in their cytoplasmic retention 
and subsequent degradation. In the absence of Hippo pathway activation, YAP and TAZ 
are able to translocate to the nucleus, where they interact with the TEAD family of 
transcription factors to induce the expression of genes associated with cell survival, 
proliferation, and migration. Thus, under normal physiological conditions in epithelial 
tissue such as the pancreatic duct, YAP/TAZ activity remains low. 
 Deregulation of Hippo signaling in PDAC is evidenced by increased YAP/TAZ 
protein levels and nuclear localization [100-102]. However, the underlying mechanisms 
accounting for increased YAP/TAZ activation remain an area of active investigation. 
Pan-cancer genomic analyses have revealed that mutations in the genes encoding Hippo 
pathway components occur at very low frequencies [97, 98]. Given the oncogenic activity 
of YAP, this is a surprising finding [103]. The low frequency of Hippo pathway gene 
mutations in human cancer could indicate that that Hippo signaling is essential for both 
physiological and pathophysiological tissue homeostasis. This notion is supported by 
several studies in which the deletion of various Hippo pathway components in mice 
results in embryonic lethality [104-108]. Therefore, pathway output must be 
physiologically maintained within certain limits to ensure that cellular proliferation 
remains in check. 
 The mechanisms that control YAP/TAZ activation in PDAC have yet to be fully 
elucidated. One possible mechanism is loss of LATS1/2 expression as a consequence of 
promoter hypermethylation. Epigenetic regulation of the Hippo pathway, which has been 
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documented in both colon and breast cancers [109, 110], functionally disconnects 
YAP/TAZ activity from upstream pathway induction. Another alteration that may 
account for the elevated YAP/TAZ levels in PDAC is gene amplification. YAP and TAZ 
gene copy number gains have been documented in several different cancer types [97, 
111]. In such contexts, increased YAP/TAZ protein levels result in constitutive activation 
even when the Hippo pathway is intact and active. 
 Recent studies of YAP function in GEMMs suggest that it plays a key role in 
PDAC initiation and maintenance. Ectopic expression of YAP in the developing mouse 
pancreas results in the appearance of metaplasia and impaired differentiation of both the 
endocrine and exocrine compartments [112, 113]. However, increased organ size and 
tumor formation were not observed. Subsequent work in Kras and Kras/Tp53-mutant 
mice demonstrated that YAP is essential for the progression of neoplasia to PDAC [102]. 
Furthermore, YAP gene amplification is observed in some cases following loss of 
oncogenic KRAS expression in GEMMs and cancer cell lines, leading to increased cell 
survival and tumor recurrence [35, 36]. In these studies, YAP activity can bypass the 
requirement for sustained KRAS signaling, conferring a loss of KRAS oncogene 
dependence. Furthermore, YAP can become activated as a consequence of MAPK 
signaling to promote survival and proliferation. Hence, the loss of KRAS expression in 
PDAC GEM models initially results in robust tumor regression. However, a 
subpopulation of cells with amplification and overexpression of YAP, is able to 
repopulate the tumor, leading to disease relapse. Collectively, these studies suggest that 
Hippo pathway deregulation plays a critical role in PDAC progression as well as 
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dependence on the KRAS-MAPK pathway. Thus, modulation of YAP and/or TAZ 
activity represents an attractive opportunity for therapeutic intervention. 
 
c. Inflammation 
 Innate immune responses and inflammation have been associated with cancer 
etiology in many contexts, and pancreatic cancer is no exception. Recent studies using 
KRAS-driven GEM models have highlighted the role of acute pancreatitis-associated 
inflammation in driving the progression of PanIN lesions to full-blown PDAC [114]. 
Some studies estimate that up to 50% of the PDAC tumor cell mass can be composed of 
stromal and immune cells recruited to the tumor via paracrine cytokine signaling [115]. 
Furthermore, oncogenic KRAS signaling can promote the development of the 
inflammatory microenvironment found in PDAC tumors. It is hypothesized that 
inflammation promotes PDAC initiation and progression through several different 
mechanisms. Firstly, it promotes cell survival and proliferation through inflammatory 
mediators that activate transcription factors responsible for antiapoptotic signaling as well 
as cancer cell invasion and metastasis. Examples of such proinflammatory, pro-survival 
transcription factors include STAT3, the AP-1 complex (Jun/Fos), and NF-κB. KRAS 
induces IL-6 and IL-11 cytokine expression and secretion, leading to STAT3 
transcriptional activation. KRAS also promotes NF-κB signaling via induction of the 
MAPK pathway, leading to increased TNFα and IL-1 levels, which drive a positive 
feedback loop for NF-κB activation. Reciprocally, NF-κB can enhance RAS activity 
through a RAS-NF-κB-cyclooxygenase-2 positive feedback loop [68]. Thus, 
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inflammatory cytokines and RAS signaling are intimately linked. Secondly, 
proinflammatory cytokines, including TNFα, IL-6, and IL-1, can promote metastasis by 
inducing EMT as well as the acquisition of cancer stem cell-like traits [115]. These 
mechanisms, coupled with the ability of NF-κB to activate Notch and other oncogenic 
pathways, lead to accelerated PDAC development. Finally, inflammation-associated 
cytokines can impair immunosurveillance of tumor cells due to an increase in immune 
cell subsets that have immunosuppressive properties, including regulatory T-cells (T-
regs) and myeloid-derived suppressor cells (MDSCs). These cell types can negatively 
regulate the numbers and functional activation of cytotoxic CD8+ T-cells, possibly via 
increased expression of granulocyte-macrophage colony-stimulating factor (GM-CSF) 
[116, 117]. 
 There are likely to be a number of additional and diverse mechanisms by which 
inflammation promotes cancer. Inflammation can cause cellular damage, for example, via 
the accumulation of reactive oxygen species (ROS) that promote oxidative DNA damage 
[115]. This may lead to increased genetic evolution in PDAC development as tumor cells 
acquire somatic mutations that confer selective advantages to promote growth and 
survival. When cells acquire an activating oncogenic mutation (e.g. KRAS), a 
phenomenon known as oncogene induced senescence (OIS) is triggered as a consequence 
of CDKN2A/p16 induction. This senescence response can be suppressed by inflammatory 
signaling, representing a mechanism by which inflammation promotes cancer 
progression. Taken together, inflammation clearly plays a critical role in 
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immunosuppression, KRAS pathway modulation, and cancer metastasis. Thus, targeting 
inflammatory pathways could represent an attractive avenue for therapeutic intervention. 
 
d. Autophagy 
 Autophagy is a well-characterized metabolic, homeostatic process by which 
cellular constituents, such as proteins and organelles, are degraded and recycled to meet 
cellular demands under conditions of nutrient deprivation or stress. Such conditions occur 
during tumorigenesis, and indeed, constitutive activation of autophagy has been observed 
in many tumors including PDAC [118, 119]. Three types of autophagy are typically 
described: macroautophagy, microautophagy, and chaperonin-mediated autophagy. 
Macroautophagy, henceforth referred to simply as autophagy, is the primary pathway, as 
well as the most significant in PDAC. During nutrient deprivation, misfolded and non-
essential proteins, as well as organelles, are sequestered into a lipid bilayer known as a 
phagophore. This gives rise to a double-membrane structure known as the 
autophagosome, which subsequently fuses with a lysosome, forming an 
autophagolysosome, or autolysosome. The presence of degradative enzymes combined 
with low pH within autolysosomes cause the breakdown of cellular macromolecules. 
Amino acids and other building blocks are then recycled, allowing for cellular 
homeostasis to be maintained. In normal pancreatic tissue, there is a basal level of 
autophagy that serves to maintain homeostasis [118]. 
 The role of autophagy in pancreatic cancer is complicated and has yet to be fully 
elucidated. PDACs typically exhibit high basal levels of autophagic activity, including 
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increased number and size of both autophagosomes and autolysosomes, when compared 
to normal pancreatic tissue [120]. It is hypothesized that tumor cells gain a selective 
advantage when autophagy is activated, as it may allow them to cope with the stresses 
resulting from high rates of cell division as well as nutrient deprivation, which can occur 
from hypoxic conditions in poorly vascularized regions of the tumor [121]. Therefore, 
autophagy can drive the survival of PDAC cells under these conditions. Chloroquine, 
which inhibits autophagy by blocking the formation of autolysosomes, potently 
suppresses the growth of some PDAC cell lines. When autophagy is inhibited with 
chloroquine, or by genetic ablation of the key autophagy regulator Atg-7, Kras-induced 
progression of PanIN to PDAC is blocked as a consequence of cell death, growth arrest, 
or senescence [122]. However, when combined with TP53 deletion, Atg-7 loss enhances, 
rather than suppresses, Kras-driven PDAC progression [123]. These findings highlight 
the highly context-dependent role of autophagy in PDAC pathogenesis, which depends 
on TP53 status and possibly other tumor suppressor gene mutations. Lastly, autophagy 
could allow PDAC cells to cope with the deleterious effects of chemotherapeutics and 
radiation therapy. For example, treatment of the PDAC cell line PANC-1 with 
gemcitabine or 5-fluorouracil induces autophagy [121]. Interestingly, the combination of 
autophagy inhibitors, such as chloroquine, with chemotherapy or radiation therapy 
greatly enhances cytotoxicity in PDAC cell lines. 
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6. Current and Future Therapeutic Strategies for Pancreatic Cancer 
 PDACs are notoriously difficult to treat for a number of reasons [9]. Most patients 
with PDAC are often asymptomatic, and diagnoses are not usually made until after the 
tumors have become metastatic. Currently, there are few effective therapeutic options for 
PDAC patients. The only “curative” treatment is surgical resection, but its success rate in 
patients with operable tumors is low, with a 5 year survival rate of only 20%, a 60% rate 
of relapse within 6 months, and an overall relapse rate of more than 80%. Due to the 
typically late diagnosis, many patients are not candidates for surgical resection. In 
contrast, chemotherapy has marginal, but measureable, effects on overall survival in 
PDAC patients. The efficacy of chemoradiation as a PDAC therapeutic regimen remains 
unclear when compared to chemotherapy alone. With current PDAC therapeutic options, 
overall survival of 5 years or greater is estimated to be less than 5%, and these rates have 
not changed significantly in the past 30 years. Understanding PDAC etiology and 
pathogenesis at the detailed molecular level as a means to developing better therapeutics 
to treat the disease remains a pressing goal. PDAC is a complex disease with multiple 
stages that will respond to different sets of anticancer agents. The complexity of this 
disease is further highlighted by recent studies using a PDAC GEM model demonstrating 
that cells from PanIN lesions can metastasize. Pancreatic epithelial cells are able to 
disseminate from the pancreas at an early stage of the disease, when a primary lesion is 
not yet detectable. These cells are capable of seeding in the liver and potentially other 
distant sites. Therefore, therapeutics may be more successful if they are designed to treat 
pancreatic cancer as a systemic disease rather than localized one [124]. This could 
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explain the low rate of success with local treatment, as cancer cells may be present at 
distal sites such as the liver or the lymph nodes. It is clear that new approaches to treat 
PDAC must be developed. A number of innovative avenues for therapeutic intervention 
are currently being evaluated in basic science and clinical studies [9]. 
 For PDAC patients with resectable lesions, the standard of care involves surgical 
resection and adjuvant chemotherapy with gemcitabine or 5-fluorouracil (5-FU). Both 
agents are pyrimidine analogs that block various stages of DNA replication, leading to 
cell cycle arrest and, in some cases, apoptosis. These conventional cytotoxic agents 
preferentially target rapidly dividing cells and can lead to modest tumor regression or 
growth suppression. In metastatic disease, the standard of care is a drug regimen that 
consists of gemcitabine, FOLFIRINOX, or nab-paclitaxel. FOLFIRINOX is a 
combination chemotherapy made up of folinic acid (leucovorin), 5-FU, irinotecan, and 
oxaliplatin. These agents collectively interfere with DNA replication and transcription. 
Paclitaxel, on the other hand, binds to, and stabilizes, microtubules, preventing their 
disassembly and ultimately blocking progression through mitosis. Nab-paclitaxel is an 
albumin-bound form of the drug that has increased bioavailability. As these drugs 
indiscriminately target all rapidly dividing cells, many side-effects and dose-limiting 
toxicities are associated with their utilization. For this reason, conventional cytotoxic 
chemotherapeutics provide only marginal increases in median patient survival on the 
order of weeks or months [9]. To improve the survival benefit conferred by these agents, 
many ongoing studies are investigating optimal dosing regimens and combinations for 
treating different stages of pancreatic cancer. Clinical trials involving chemoradiotherapy 
  
37
have returned inconsistent results, and the treatment remains controversial. This is 
possibly due to the lack of biomarkers to determine which patients will be responsive to 
radiation treatment. A newer strategy involves gemcitabine in combination with the 
EGFR tyrosine kinase inhibitor erlotinib, which results in a modest survival benefit of 12 
days compared to gemcitabine alone. Thus, erlotinib is the only FDA-approved targeted 
therapy available for treatment of pancreatic cancer. Some patients respond much more 
favorably to erlotinib than others, suggesting that there could be biomarkers to identify 
PDAC patients who will likely benefit most from anti-EGFR therapies such as erlotinib. 
A recent study found that TP53-wild-type tumors may be more sensitive to EGFR 
inhibition. Thus, identifying the right patient population for a particular targeted therapy, 
in the interests of precision medicine, remains a key goal of PDAC therapeutics [9]. 
 Effective targeted therapeutics and precision medicine-based approaches for 
PDAC have yet to be identified. One approach under investigation is to take advantage of 
the tumor specific environment. Due to the high density of fibrous connective tissue that 
is characteristic of pancreatic cancer, drug delivery to tumors is severely impaired. 
Hyaluronic acid is an extracellular matrix component found surrounding tumors that 
presents a physical barrier for drug delivery. The degradation of hyaluronic acid via 
hyaluronidase may enhance drug delivery. PEGPH20 is a PEGylated form of 
hyaluronidase that is currently being tested and shows prolonged survival of tumor-
bearing mice when given in combination with gemcitabine [125]. DNA damaging agents 
such as TH-302 (evofosfamide) can take advantage of the hypoxic environment in 
pancreatic tumors to increase their specificity. This drug is derived from a nitrogen 
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mustard that becomes activated under hypoxic conditions and releases its active form, 
dibromoisophosphoramide mustard (Br-IDM), a DNA alkylating agent. In combination 
with gemcitabine, TH-302 provides a 6 month survival benefit compared to 3.6 months 
with gemcitabine alone [126, 127]. Drug modifications that provide improved delivery 
are also being evaluated, such as nab-paclitaxel or nanoliposomal formulations of 
irinotecan (MM-398). These modifications can increase the plasma half-life of drugs and 
increase the availability of their active metabolites. MM-398 provides a 2-month survival 
advantage when given in combination with 5-FU and folinic acid [128]. To identify 
accurate biomarkers of response to particular agents, DNA sequencing of PDACs for 
sensitizing genetic alterations represents a major step in advancing precision medicines to 
treat the disease. Some examples currently under investigation include SMAD4 for 
chemoradiotherapy, STK11 for mTOR inhibitors, and the genes PALB2, ATM, and 
BRCA2 for DNA damaging agents [9]. 
 Another avenue for therapeutic intervention could be to exploit oncogene 
“addiction” [129]. As mutant KRAS is a key linchpin in PDAC pathogenesis, it remains a 
major therapeutic target, albeit a stubborn one. Thus far, there has been little success in 
targeting the RAS-related proteins, due to their high affinity for GTP and the abundance 
of GTP in the cell, which prevent access to the protein active site. Nonetheless, many 
alternate methods of RAS inhibition are currently being investigated. The RAS protein 
must undergo several post-translational modifications, including a farnesylation step, 
before the protein is functional. Blocking farnesylation of the protein is one potential 
method to inhibit the RAS pathway, but results have been disappointing thus far because 
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KRAS can be alternatively isoprenylated with a geranylgeranyl group. After the RAS 
protein has been translated, it must be transported to the cell membrane, a process that 
requires the PDEδ protein. Thus, the PDEδ inhibitor Deltarasin has been developed, 
which can block RAS membrane translocation. This prevents the downstream activation 
of ERK, leading to suppression of KRAS driven PDAC cell proliferation and viability. 
Although directly inhibiting KRAS has proven to be difficult, allosteric, covalent-
modifying inhibitors that stabilize the GDP bound form of the protein have been 
identified for the G12C isoform commonly found in non-small cell lung cancer 
(NSCLC). It is possible that a similar agent could be identified for the most common 
isoform found in pancreatic cancer, KRAS G12D. As direct inhibition of KRAS remains 
a challenge, downstream inhibition of the RAF-MEK-ERK cascade and/or PI3K/mTOR 
has become an active area of investigation [9, 19]. Lastly, synthetic lethality is another 
approach that attempts to identify genetic interactors with mutant KRAS that cooperate to 
promote PDAC tumor cell survival [129]. Thus far, genome-wide KRAS synthetic 
lethality siRNA screens have failed to yield promising candidate therapeutic targets, 
perhaps due to the complexity and molecular heterogeneity of oncogenic KRAS mutant 
PDAC tumors. 
 Altered cellular metabolism is yet another area being studied to develop PDAC 
therapeutics. In the tumor microenvironment, dense desmoplastic regions surround the 
tumor, leading to hypoxia and decreased nutrient delivery to cells. Tumors with increased 
glycolysis gain a survival advantage in the hypoxic environment (known as the Warburg 
effect), and autophagy is induced in response to nutrient deprivation. As described above, 
  
40
chloroquine, or its derivative hydroxychloroquine, inhibits autophagy by blocking the 
formation of autolysosomes. While chloroquine alone is mildly effective in promoting 
PDAC cell death, studies indicate that it can sensitize tumors to MEK inhibitors, 
chemoradiotherapy, gemcitabine, and nab-paclitaxel [130, 131]. 
 Finally, immunotherapy is an exciting field in cancer therapeutics that has 
demonstrated dramatic effects in other diseases, such as melanoma. This approach 
employs activation of the host immune system to combat tumors by promoting tumor cell 
clearance via cytotoxic T-cells. The immunosuppressive environment found in pancreatic 
cancer prevents immunosurveillance of tumors from occurring efficiently. Thus, 
supercharging the immune system to overcome this immunosuppression represents an 
innovative therapeutic strategy. One approach is to sensitize the immune system to 
pancreatic cancer cells through vaccination. GVAX pancreas is created from whole tumor 
cells, which are genetically engineered to express granulocyte-macrophage colony-
stimulating factor (GM-CSF) and then irradiated to prevent cell division. These 
engineered pancreatic cancer cells are capable of recruiting dendritic cells that can 
phagocytose the tumor cells, which are subsequently presented to T-cells to promote their 
activation and ability to recognize and clear tumor cells [132]. Along the same lines, T-
cells can be modified to express chimeric antigen receptors that recognize tumor 
antigens. This approach has been successfully achieved in CD19-positive hematological 
malignancies but is still in early development for pancreatic cancer [133]. CD40, a cell 
surface protein on antigen presenting cells plays a key role in immune cell activation. 
Thus, CD40 agonists are being tested in combination with gemcitabine to promote 
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accumulation of phagocytic macrophages in tumors [134]. PD-L1 and PD-L2 are ligands 
expressed by cancer cells capable of binding to the immune checkpoint receptor PD-1 on 
activated CD8+ T-cells, causing suppression of cytotoxic T-cell function. This impairs 
immunosurveillance of cancer cells. Monoclonal antibodies that target PD-L1 or PD-1, 
such as pembrolizumab, have been developed to promote CD8+ T-cell activation. These 
agents have yielded significant beneficial results in melanoma, non-small cell lung 
cancer, and renal cell carcinoma. As is the case with these malignancies, PD-L1 
expression in pancreatic tumors is also associated with a poor prognosis [88]. 
Monoclonal antibodies against CTLA4 (e.g. ipilimumab), another T-cell immune 
checkpoint receptor, have also been tested in pancreatic cancer [135]. Unfortunately, 
checkpoint inhibitors have had disappointing results as single therapies in PDAC thus far. 
However, there is hope that they will be effective in combination with other 
chemotherapeutics, such as gemcitabine and nab-paclitaxel. In summary, PDAC remains 
one of the most deadly of all human diseases due a severe lack of effective therapeutics. 
Innovative therapeutic approaches for PDAC include optimizing the dosing regimens of 
current agents, targeting oncogene addiction, manipulating tumor metabolism, and 
harnessing the host immune system to fight this aggressive cancer type. 
 
7. Conclusions 
 Pancreatic ductal adenocarcinoma is a highly aggressive malignancy associated 
with very poor clinical prognosis. Although the core genetic alterations in PDAC are well 
documented, their contributions to PDAC pathogenesis remain to be fully determined at 
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the molecular level. Next generation sequencing has revealed the detailed complexity of 
the genomic landscape of PDAC, which is characterized by marked inter- and intratumor 
heterogeneity as well as a very high overall mutational burden. Gene mutations in PDAC 
have been shown to converge on a few critical signal transduction pathways and cellular 
processes including the KRAS-MAPK pathway, inflammation, and altered cellular 
metabolism. The complexity of PDAC pathogenesis is further illustrated by the 
classification of PDAC tumors into four major molecular subtypes that are distinguished 
by key phenotypic traits and pharmacological vulnerabilities. Detailed characterization of 
these subtypes could ultimately lead to the development of new precision medicines for 
treating PDAC. However, current therapeutic options for the disease remain limited. 
Understanding and attacking the complexity of PDAC pathogenesis will undoubtedly 
yield additional innovative therapeutic options for this aggressive and deadly disease. 
 
B. The NDR/LATS Kinase Family 
1. Introduction 
 The NDR (nuclear Dbf2-related) and LATS (large tumor suppressor) kinases 
comprise a subfamily of AGC serine/threonine protein kinases [136, 137]. They include 
NDR1/2, also known as STK38/STK38L, and LATS1/2. The NDR/LATS kinases are 
evolutionarily conserved from yeast to humans [138]. The degree to which they are 
conserved is so significant that STK38 and LATS1 can functionally rescue the loss of 
their related orthologs in Drosophila melanogaster, Tricornered (Trc) and Warts (Wts) 
[139, 140]. As discussed in subsequent sections, the NDR/LATS kinases play roles in 
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development, cell proliferation, cell cycle regulation, apoptosis, autophagy, and 
ciliogenesis. Additionally, these kinases can promote or prevent the development of 
various malignancies in a context-dependent manner. 
 
2. Structure 
 The NDR/LATS kinases are classified as AGC serine/threonine protein kinases 
based on the sequence of their catalytic domain [136, 137]. Like all AGC kinases, they 
are activated by the phosphorylation of two highly conserved regulatory motifs: the 
activation sequence (also known as the T-loop) and the hydrophobic motif (Fig. 3) [141-
147]. However, the NDR/LATS kinases can be distinguished from other AGC kinases 
based on two unique features: a conserved N-terminal regulatory (NTR) domain and an 
insert of 30-60 amino acids within the catalytic domain [138, 148, 149]. The sequence of 
the 30-60 residue insert is not conserved across the kinase subfamily. However, the C-
terminal portion of it is rich in basic amino acids. Mutation of these residues to alanine 
has been shown to enhance NDR kinase activity [150]. Hence, this cluster of basic 
residues is referred to as the auto-inhibitory sequence. The activation sequence of the 
NDR/LATS kinases is located within subdomain VIII of the catalytic domain, which 
consists of twelve subdomains in total [136, 148]. It is preceded directly by the auto-
inhibitory sequence, which is located within the linker region between subdomains VII 
and VIII [138, 150]. Another key feature of the catalytic domain is a lysine residue 
located in subdomain II. Mutation of this lysine residue to alanine or arginine renders the 
NDR/LATS kinases catalytically inactive [143, 144, 148, 151-154]. The hydrophobic 
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motif that regulates kinase activation is not found within the catalytic domain. Rather, it 
is located at the C-terminal end of the NDR/LATS kinases [138, 141]. In summary, the 
NDR/LATS kinases share three key regulatory structures: the NTR, the catalytic domain, 
and the hydrophobic motif. 
 
Figure 3. Schematic of key features related to NDR/LATS kinase regulation and function. Activation 
of the NDR/LATS kinases requires phosphorylation of two regulatory domains: the activation segment 
(AS) and the hydrophobic motif (HM). Residues phosphorylated within these domains are listed above. 
Also shown are the N-terminal regulatory (NTR) domain and the lysine residue required for kinase activity. 
Figure adapted from Hoa et al., 2016. 
 Despite their numerous structural similarities, the NDR/LATS kinases differ 
significantly in their N-terminal region [138]. The N-terminal regulatory (NTR) domain 
comprises nearly the entire N-terminus of the NDR kinases. In contrast, the segment 
preceding the NTR of the LATS kinases is substantially larger and contains additional 
regulatory domains [155]. The N-termini of LATS1/2 share a low degree of sequence 
homology [153, 156]. However, they do contain two conserved domains known as LATS 
conserved domains (LCDs) 1 and 2. Deletion of these LCDs impairs the tumor 
suppression function of LATS1/2, suggesting that they are necessary for normal kinase 
function [154, 157]. Thus, the LATS kinases, by virtue of having a larger N-terminus 
than the NDR kinases, possess additional domains beyond the activation segment and 
hydrophobic motif that influence their activity. 
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3. Regulation 
 The NDR/LATS kinases are mechanistically regulated in a similar manner. 
Ultimately, phosphorylation of the activation segment and hydrophobic motif is required 
for maximal kinase activation (Fig. 4). All four kinases are phosphorylated by the 
mammalian sterile twenty-like (MST) 1/2 kinases at a single threonine residue in the 
hydrophobic motif (T444 for STK38, T442 for STK38L, T1079 for LATS1, and T1041 
for LATS2) [145, 158-160]. Additionally, the NDR/LATS kinases can autophosphorylate 
a single serine residue in the activation segment (S281 for STK38, S282 for STK38L, 
S909 for LATS1, and S872 for LATS2) [143-145, 147, 148]. NDR kinase 
autophosphorylation requires the binding of human Mps one binder (hMOB) kinase 
activator 1A/B to the NTR [150]. hMOB1A/B also bind to the NTR of LATS1/2 [146, 
161, 162]. As with the NDR kinases, this interaction promotes LATS2 
autophosphorylation [147]. However, it remains unclear whether hMOB1A/B are 
required for LATS1/2 autophosphorylation. Nevertheless, multiple studies have 
demonstrated that hMOB1A/B are necessary for activation of the entire kinase subfamily 
[108, 146, 147, 150, 159, 163]. Inactivation of the NDR/LATS kinases also occurs via a 
shared mechanism: dephosphorylation of both the activation segment and the 
hydrophobic motif by the protein phosphatase 2A (PP2A) [142-144, 146, 164]. Thus, the 
entire NDR/LATS kinase family can be regulated via a common series of mechanisms. 
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Figure 4. Mechanisms of NDR kinase regulation. STK38/STK38L are activated by the phosphorylation 
of a threonine residue in the hydrophobic motif (HM) and a serine residue in the activation segment of 
catalytic domain. Briefly, hMOB1A/B binds to the NTR of STK38/STK38L and promotes 
autophosphorylation of the activation segment. The HM is phosphorylated by upstream kinases. Both 
phosphorylations are required for kinase activation. PP2A can deactivate STK38/STK38L by 
dephosphorylating the activation segment and hydrophobic motif. Figure adapted from Hoa et al., 2016. 
 Additional mechanisms of regulation have been documented for the NDR/LATS 
kinases that do not extend across the entire kinase subfamily. For example, MST3 has 
been shown to phosphorylate the hydrophobic motif of both STK38/STK38L but not 
LATS1/2 [151, 165]. Similarly, the mitogen-activated protein kinase kinase kinase 
kinases (MAP4Ks) 1-7 have been shown to phosphorylate the hydrophobic motif of 
LATS1/2 [166, 167]. However, it has not been determined whether STK38/STK38L are 
substrates of the MAP4Ks. LATS1/2 activity can also be positively modulated, 
particularly in the context of mitosis, via the phosphorylation of several additional 
residues located in the N-terminus by Cdk1/cyclin B, aurora kinase A, checkpoint kinases 
1 and 2 (CHK1/2), and protein kinase A (PKA) [163, 168-171]. Similar phosphorylation 
sites are not present in STK38/STK38L, as both kinases have substantially smaller N-
termini than LATS1/2 [138]. Mechanisms of NDR kinase inhibition, both of which 
involve competitive binding interactions, have also been identified. First, hMOB2 can 
bind to the NTR of STK38/STK38L [172]. This interaction prevents hMOB1A/B from 
binding to the NTR and promoting kinase autophosphorylation. LATS1/2 are not 
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inhibited via this mechanism because hMOB2 cannot bind to the NTR of either kinase 
[146, 161]. STK38/STK38 can also be inhibited via the binding of molecule interacting 
with CasL protein 1 (MICAL-1) to their hydrophobic motif [173]. As a result, MST1 is 
unable to bind and phosphorylate the NDR kinases at this regulatory domain. Ultimately, 
the mechanisms previously described illustrate the complexity of NDR/LATS kinase 
regulation. 
 
4. Roles in Development 
 Studies of the NDR/LATS kinases in GEMMs suggest that all four kinases play a 
role in development. However, the relative importance of each kinase in this process 
varies. LATS1 knockout mice are viable but exhibit defects in growth, fertility, and 
mammary gland development [174]. Furthermore, these mice are characterized by 
pituitary dysfunction. LATS2 knockout is embryonic lethal in mice, likely due to defects 
in mitosis that promote genomic instability [104, 162]. Loss of LATS2 has also been 
shown to cause multiple cardiac defects [104, 175, 176]. At present, LATS1/2 double-
knockout mice have not been documented. However, given that deletion of LATS2 alone 
is lethal, it is unlikely that the loss of LATS1/2 would be tolerated. This is supported by 
studies in preimplantation mouse embryos, where the loss of both LATS1/2 causes a 
failure to distinguish the trophectoderm from inner cell mass [177, 178]. Thus, LATS1/2 
both play important, yet nonequivalent, roles in development. 
 STK38/STK38L have not been studied in the context of development to the same 
extent as LATS1/2. Nevertheless, STK38 and STK38L single gene knockouts do not 
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cause any discernable phenotypic defects in mice [179, 180]. This is likely due to 
functional overlap, as knockout of either gene alone is associated with increased 
expression of the other kinase isoform. Co-deletion of STK38 and STK38L causes defects 
in somitogenesis and cardiac looping, resulting in embryonic lethality [180]. Thus, while 
STK38 and STK38L are functionally redundant, both kinases play critical roles in 
development. Several studies have suggested that both kinases are also be involved in 
neuronal development, as they regulate dendrite growth and spine development in 
addition to neuronal polarity [181-184]. However, the in vivo relevance of these findings 
has not been thoroughly addressed. Thus, the roles of STK38 and STK38L in neuronal 
development require further investigation. 
 
5. NDR/LATS Kinase Functions 
a. The Hippo Tumor Suppressor Pathway 
 The NDR/LATS kinases all function as effectors in the Hippo tumor suppressor 
pathway. LATS1/2 have been extensively characterized in this context. Acting 
downstream of the MST1/2 and MAP4K kinases [145, 166, 167], LATS1/2 
phosphorylate the transcriptional co-activators YAP and TAZ at multiple sites [185, 186]. 
This results in the cytoplasmic retention and subsequent degradation of YAP/TAZ [187, 
188]. When in a hypophosphorylated state, YAP/TAZ localize to the nucleus, where they 
bind to TEAD family transcription factors and promote the expression of genes that 
promote cellular proliferation and survival [99, 189, 190]. STK38/STK38L also exhibit 
the ability to phosphorylate YAP [191]. However, it has not been determined whether 
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TAZ is also a substrate of these kinases. Additionally, the upstream activators of 
STK38/STK38L in this signaling cascade have not been determined. Previous work has 
demonstrated that both kinases are activated by MST1/2/3 [151, 158-160, 165, 173, 192]. 
Thus, it is possible that STK38/STK38L, like LATS1/2, function downstream of the 
MST kinases in the context of Hippo signaling. 
 Although the NDR/LATS kinases all regulate YAP activity, they are not 
functionally equivalent in this context. Early work suggested that LATS1/2, but not 
STK38/STK38L, were YAP kinases [185]. This conclusion was based on two 
observations. First, only LATS1/2 were shown to interact with YAP by co-
immunoprecipitation. Second, overexpression of wild-type LATS1/2 resulted in the gel-
shift of YAP when examined by Western blot. This shift was not observed when kinase-
dead variants of LATS1/2 or wild-type STK38/STK38L were overexpressed. Thus, it 
was thought for several years that STK38/STK38L were not YAP kinases. Subsequent 
work refuted this notion, demonstrating that both kinases phosphorylate YAP at four of 
the same residues as LATS1/2: S61, S109, S127, and S164 [191]. However, 
STK38/STK38L do not phosphorylate YAP at S381, another LATS1/2 target site. This 
discrepancy suggests that the NDR/LATS kinases do not regulate YAP equivalently. 
 YAP activity can be positively or negatively regulated by direct phosphorylation. 
The NDR/LATS kinases all inhibit YAP via this mechanism. Nevertheless, each of the 
residues phosphorylated by these kinases influence YAP activity in different ways. 
Phosphorylation of S61 inhibits the ability of YAP to induce gene expression [193]. 
However, it does not appear to have any effect on YAP protein stability or subcellular 
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localization. Phosphorylation of S127 creates a site for the 14-3-3 protein to bind YAP 
and sequester it in the cytoplasm [101, 194-196]. As a result, YAP is unable to induce 
gene expression by virtue of being excluded from the nucleus. Phosphorylation of S381 
results in the degradation of YAP [187]. A similar observation has been made with S109, 
but this effect has only been documented when T110 is also phosphorylated [197]. As 
T110 is not a NDR/LATS kinase target site, it is unclear whether phosphorylation of 
S109 alone is sufficient to cause YAP degradation. However, a functional study of YAP 
suggests that phosphorylation of either S109 or S164 has no effect [187]. Further 
characterization of these residues is required to understand how they might 
mechanistically regulate YAP activity. Ultimately, the NDR/LATS kinases all inhibit 
YAP by phosphorylation of multiple residues. Nevertheless, the inability of 
STK38/STK38L to phosphorylate S381 suggests that the two kinases may not regulate 
YAP as robustly as LATS1/2. Addressing these functional differences could provide 
greater insight regarding how the Hippo pathway regulates cell survival and proliferation. 
 
b. Cell Cycle Regulation 
 The NDR/LATS kinases can positively or negatively regulate the cell cycle. As 
previously discussed, the entire kinase family can restrict cell proliferation by directly 
phosphorylating the transcriptional co-activator YAP [185, 191]. This activity inhibits the 
ability of YAP to induce the expression of genes that promote cell cycle progression [99]. 
LATS1/2 can also block cell cycle progression by inhibiting the cyclin dependent kinase 
1 (Cdk1; also known as Cdc2). However, LATS1 and LATS2 may inhibit Cdk1 via 
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distinct mechanisms. LATS1 binds to Cdk1 and prevents it from associating with cyclin 
B [140]. LATS2 has not been shown to associate with Cdk1, but overexpression of the 
kinase promotes phosphorylation of the cell division cycle 25 homologue A (CDC25A) 
phosphatase at S216 [198]. This inhibits the ability of CDC25A to dephosphorylate and 
activate Cdk1. LATS2 can also promote G1/S arrest by downregulating Cdk2 kinase 
activity, possibly through CDC25A [154]. Like LATS1/2, STK38 can block cell cycle 
progression by modulating of CDC25A. STK38 directly phosphorylates CDC25A at S76 
in response to DNA damage [199]. This results in the degradation of CDC25A, 
preventing the phosphatase from activating multiple cyclin-dependent kinases, including 
Cdk1 [200]. Loss of CDC25A expression via this mechanism induces G2/M arrest. 
Together, the studies described demonstrate that the NDR/LATS kinases can negatively 
modulate the cell cycle via a series of interrelated mechanisms. 
 LATS2 can also block cell cycle progression via a distinct mechanism not shared 
with the other NDR/LATS kinases: stabilizing the transcription factor p53. LATS2 binds 
to and inhibits MDM2, an E3 ubiquitin ligase that promotes the degradation of p53 [201]. 
This activity stabilizes p53, allowing it to induce expression of the cyclin-dependent 
kinase inhibitor p21 and ultimately cause cell cycle arrest at G1/S [201, 202]. Thus, 
LATS2 can block the cell cycle at multiple stages by modulating the stability of p53 and 
other regulatory proteins. 
 Additional work has demonstrated that the NDR/LATS kinases also positively 
contribute to cell cycle progression. All four kinases play a role in multiple aspects of 
mitosis including centrosome duplication, chromosome alignment, and chromosome 
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segregation [104, 140, 157, 159-162, 168, 170, 172, 198, 203-210]. Furthermore, 
LATS1/2 are involved in the regulation of cytokinesis. In addition to mitosis, 
STK38/STK38L can promote cell cycle progression through G1/S by directly 
phosphorylating the cyclin-dependent kinase inhibitor p21 at S146 [151, 211, 212]. This 
phosphorylation results in the degradation of p21 and promotes entry into S-phase of the 
cell cycle. STK38/STK38L can also promote cell proliferation by stabilizing the 
transcription factor c-Myc [151, 213-215]. As a result, c-Myc is able to induce the 
expression of various genes that promote cell cycle progression and repress the 
expression of those genes that inhibit it [216]. At present, the precise mechanism by 
which STK38/STK38L stabilize c-Myc is unclear. Both kinases directly bind to c-Myc 
and inhibit F-box and WD repeat domain-containing 7 (FBW7)-mediated ubiquitination 
of the transcription factor [151, 213]. However, STK38/STK38L do not compete with 
FBW7 to bind c-Myc. The stabilization of c-Myc was originally shown to occur 
independent of STK38/STK38L kinase activity, but a subsequent study has suggested 
that c-Myc-dependent transcription may be enhanced by it [215]. Thus, STK38/STK38L 
may positively modulate the activity of c-Myc via multiple mechanisms. In addition to 
regulating p21 and c-Myc, STK38/STK38L can promote cell cycle progression by 
inhibiting TGF-β signaling [217]. Induction of the TGF-signaling pathway results in 
activation of the SMAD family transcription factors, which subsequently translocate to 
the nucleus and induce the expression of genes that cause cell cycle arrest. 
STK38/STK38L inhibit SMAD2 phosphorylation via a kinase activity-dependent 
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mechanism. This activity ultimately blocks TGF-β-induced growth arrest.  Thus, the 
NDR/LATS kinases can modulate the cell cycle in several ways. 
 
c. Apoptosis 
 The NDR/LATS kinases can promote apoptosis via several mechanisms. As 
previously described, all four kinases inhibit the transcriptional co-activator YAP by 
direct phosphorylation [185, 191]. This activity can prevent YAP from inducing the 
expression of anti-apoptotic genes, resulting in cell death [99]. Similarly, LATS1/2 can 
promote apoptosis by phosphorylating and inhibiting the YAP paralog TAZ [186]. In 
addition to regulating YAP/TAZ activity, LATS2 can promote apoptosis by stabilizing 
the transcription factor p53 [201]. This allows p53 to induce the expression of several 
pro-apoptotic genes [49, 218]. Like LATS2, STK38/STK38L can promote apoptosis 
independent of regulating YAP. Both kinases are activated downstream of Ras 
association domain family 1 isoform A (RASSF1A)/MST1 in response to Fas receptor 
stimulation and are required for the induction of apoptosis via this signaling cascade 
[158]. Furthermore, loss of STK38/STK38L alone, or in combination, can impair the 
ability of multiple proapoptotic stimuli to induce cell death [173, 179, 192]. The events 
following STK38/STK38L activation that ultimately result in apoptosis have not been 
determined. However, the kinase activity of STK38/STK38L is required for cell death to 
occur. Collectively, the NDR/LATS kinases can induce apoptosis via a series of 
overlapping and non-overlapping mechanisms. 
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d. Autophagy and Ciliogenesis 
 Recently, multiple studies have demonstrated a role for STK38 in promoting 
autophagy, the homeostatic process by which cellular constituents are degraded and 
recycled to meet cellular demands under stress conditions. The first of these studies 
revealed that RNAi-mediated depletion of STK38, but not STK38L, in HeLa cells 
impairs mitophagy, the selective degradation of mitochondria by autophagy [219]. 
Subsequent work revealed that STK38 promotes the interaction of exocyst complex 
component (Exo84) with Beclin1 and RalB via its kinase activity to initiate 
autophagosome formation [220]. Furthermore, RNAi-mediated depletion of STK38 
severely impairs this process. Thus, STK38 plays a critical role in the early steps of 
autophagy.  
 Although autophagy can enhance cell survival under stress conditions, it can also 
support tumorigenesis [119]. Hence, it is no surprise that STK38 promotes survival in 
HRAS-transformed cell lines by mediating the clearance of damaged mitochondria [212]. 
In concordance with previous findings, RNAi-mediated depletion of Exo84 or RalB 
negatively influences cell growth and viability. Furthermore, overexpression of STK38L 
fails to compensate for the loss of STK38 in the RAS-transformed cell lines. These 
observations suggest that the two closely related kinases have non-redundant functions, 
as only STK38 has been shown to promote autophagy. 
 Although STK38L has not been shown to modulate autophagy, the kinase 
promotes another cellular process that is tightly linked to it: ciliogenesis [221-223]. 
Primary cilia are antenna-like sensory organelles found on the exterior of the cell 
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membrane [224]. These organelles transduce various stimuli from the extracellular 
environment and play essential roles in tissue development and homeostasis. Ciliary 
dysfunction can cause several diseases including retinal degeneration. The role of 
STK38L as a modulator of ciliogenesis was first suggested by studies linking loss of 
STK38L kinase function to retinal degeneration in canines [225, 226]. Subsequent work 
revealed that STK38L promotes ciliogenesis by phosphorylating the GEF Rabin8 at S272 
[222]. This phosphorylation promotes the binding of Rabin8 to Sec15, a protein that is 
essential for vesicular trafficking, and ultimately stimulates ciliary membrane formation. 
The ability of STK38L to promote ciliogenesis requires that the kinase be peroxisome-
bound [223]. However, STK38L does not promote peroxisome formation. Additionally, it 
has not been determined how peroxisomes might play a role in ciliogenesis. STK38 does 
not bind to peroxisomes, which may account for why the kinase does not promote cilia 
formation. Thus, STK38L plays a crucial role in ciliogenesis via a non-redundant 
function. 
 
e. Innate and Adaptive Immunity 
 The NDR/LATS kinases play a number of diverse roles in the immune system. 
STK38 has been extensively characterized in this context, as it is most abundantly 
expressed in leukocytes relative to other tissues. Deletion of STK38 promotes the 
development of T cell lymphoma in mice [179]. However, loss of STK38 alone is not 
sufficient to cause the disease due to functional compensation by STK38L. Instead, loss 
of both kinases is necessary for mice to develop the disease [192]. T cell-specific deletion 
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of STK38 and STK38L in mice has also revealed that the two kinases promote thymocyte 
egress as well as T cell migration. Thus, STK38/STK38L play multiple roles in 
regulating T cell homeostasis and function. 
 In addition to suppressing the development of T-cell lymphoma, STK38/STL38L 
may prevent other malignancies by modulating the innate immune response. STK38 
negatively regulates Toll-like receptor 9 (TLR9) signaling in macrophages [227]. When 
activated, TLRs initiate signaling cascades that ultimately induce the expression of 
proinflammatory cytokines. However, excessive induction of these signaling cascades 
can cause immunological diseases as well as cancer. In macrophages, mitogen-activated 
protein kinase kinase kinase 2 (MAP3K2; also known as MEKK2) is activated 
downstream of TLR9 and stimulates the production of the cytokines TNF-α and IL-6. 
STK38 associates with the SMAD-specific E3 ubiquitin protein ligase 1 (Smurf1) and 
promotes Smurf1-mediated polyubiquitination of MAP3K2, resulting in MAP3K2 
degradation. STK38 negatively regulates MAP3K2 independent of its kinase activity 
[227, 228]. Instead, STK38 directly binds to both Smurf1 and MAK3K2. These binding 
interactions ultimately promote Smurf1-mediated polyubiquitination of MAP3K2 by 
virtue of bringing the two proteins in close proximity to one another. At present, it is 
unclear whether STK38L also promotes MAP3K2 degradation. However, RNAi-
mediated depletion of STK38L in mouse peritoneal macrophages induces IL-6 
expression, suggesting that the kinase may inhibit TLR9 signaling as well. Thus, 
STK38/STK38L can potentially prevent the development of autoimmunity as well as 
cancer by negatively regulating the innate immune response. 
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 Although STK38 can prevent hyperactivation of the immune system, the kinase 
may also promote it. In vitro work has demonstrated that STK38 potentiates the 
activation of NF-κB [229], a transcription factor that regulates various aspects of the 
innate and adaptive immune responses [230]. NF-κB can induce the expression of 
cytokines as well as genes that promote cellular differentiation, survival, and 
proliferation. Increased NF-κB activity has been linked to a variety of inflammatory and 
autoimmune diseases [231, 232]. It has also been shown to promote the development of 
cancer [233-235]. The mechanism by which STK38 promotes NF-κB activation is 
unclear. However, it does require the kinase activity of STK38 [229]. Ultimately, the 
ability of STK38 to promote NF-κB activation suggests that the kinase might promote the 
activation, and possibly deregulation, of the immune system. Follow-up studies are 
necessary to determine the physiological relevance of this relationship. 
 In addition to regulating NF-κB, STK38 also modulates the activity of another 
transcription factor that plays a number of roles in the immune system: c-Myc. Under 
normal physiological conditions, c-Myc regulates cell proliferation, survival, 
differentiation, metabolism, motility [236]. However, deregulation of c-Myc can promote 
the development of numerous malignancies. In the context of the immune system, 
deregulation of c-Myc can result in the development of lymphomas and leukemias as 
well as suppression of the anti-tumor immune response [237, 238]. The original study 
identifying STK38/STK38L as regulators of c-Myc demonstrated that both kinases 
stabilize the transcription factor independent of their kinase activity [179, 213]. 
Furthermore, RNAi-mediated depletion of STK38 results in decreased c-Myc protein 
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levels, but has no effect on c-Myc mRNA transcript levels, in human B cells [214]. 
Consistent with this finding, a subsequent study demonstrated that depletion of STK38 
decreases the expression of B cell-specific c-Myc target genes and suppresses tumor 
growth in vivo [215]. These observations collectively suggest that STK38 modulates c-
Myc activity in B cells and promotes deregulation of the transcription factor in this 
context. Thus, STK38 could potentially contribute to the development and/or progression 
of B-cell lymphoma.  
 The role of LATS1/2 in the immune system has not been well characterized. 
However, a recent study revealed that LATS1/2 can suppress anti-tumor immunity [239]. 
Using a series of murine syngeneic tumor models (B16, SCC7, and 4T1), the combined 
deletion of LATS1/2 was shown to inhibit tumor growth. LATS1/2-deficient tumor cells 
secrete extracellular vesicles enriched with nucleic acids. The contents of these vesicles 
activate TLRs, resulting in a type-1 interferon (IFN) response that promotes an adaptive 
immune response. Thus, by suppressing this response, LATS1/2 can promote tumor 
growth. This finding contradicts the widely held notion that LATS1/2 only suppress 
tumorigenesis and suggests that the role of both kinases in this process is more complex 
that initially thought. 
 
6. Cancer-Associated Alterations in NDR/LATS Kinase Expression 
 Studies using GEMMs have suggested that the NDR/LATS kinases all possess 
tumor suppressor function [104, 174, 179, 191]. A critical step in the pathogenesis of 
cancer is the functional loss of tumor suppressor genes, which can occur as a 
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consequence of mutation, deletion, or epigenetic silencing. LATS1/2 mutations and 
deletions occur at relatively low frequencies in human tumors [97, 240, 241]. However, 
LATS1/2 promoter hypermethylation has been documented in several types of 
malignancies [109, 110, 242-245]. These findings suggest that loss of kinase expression, 
as a consequence of epigenetic silencing, is the predominant mechanism by which 
LATS1/2 inactivation occurs. At present, studies of STK38 and STK38L are fairly 
limited. For this reason, it is only known that the expression of these kinases is lost in 
certain malignancies [179, 191]. Additional work is required to determine how these 
alterations in STK38 and STK38L expression occur. 
 Functional loss of the NDR/LATS kinases is associated with a spectrum of 
different malignancies. LATS1 expression is lost in cancers of the breast, colon, cervix, 
kidney, lung, ovary, and stomach [109, 110, 245-249]. Furthermore, LATS1 KO mice are 
prone to developing soft-tissue sarcomas and ovarian stromal cell tumors[174]. Loss of 
LATS2 expression has been documented in cancers of the breast, colon, lung, ovary, and 
prostate [110, 248-252]. Expression of both STK38 and STK38L is lost in T-cell 
lymphoma [179]. Consistent with this observation, STK38 KO mice are prone to 
developing the disease. Furthermore, nearly all tumors analyzed from these mice exhibit 
loss of STK38L expression. This finding suggests that STK38/STK38L function 
redundantly as tumor suppressors in the context of T-cell lymphoma. In concordance 
with this notion, T cell-specific deletion of either STK38 or STK38L alone fails to cause 
the disease [192]. Rather, co-deletion of both genes results in T-cell lymphoma. The 
mechanism underlying the tumor suppressor function of STK38/STK38L in this context 
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is unclear. However, it may be related to the role that both kinases play in Fas receptor-
mediated induction of apoptosis [158, 179, 192]. STK38/STK38L may also have tumor 
suppressor function in prostate cancer. Loss of mRNA expression has been documented 
for both kinases in this context [253-256]. Although this finding would suggest that 
STK38 and STK38L might hinder tumor development, the role of both kinases in 
prostate cancer has not been addressed. Recent work has suggested that STK38L also 
functions as a tumor suppressor in the colon by regulating the transcriptional co-activator 
YAP [191]. However, kinase expression varied considerably when assessed in human 
tumors. Thus, STK38L tumor suppressor function may only be relevant in a subset of 
colon cancers. Although alterations in STK38L expression have been observed in 
multiple cancers [179, 191], STK38L KO mice do not appear to develop any 
malignancies [180]. Thus, the tumor suppressor function of the kinase may be fairly weak 
or highly context-dependent. 
 Additional studies have identified several types of malignancies in which STK38 
and/or STK38L expression is upregulated at the mRNA level. The increased expression of 
both kinases would suggest that they do not have tumor suppressor function in these 
contexts. Rather, STK38/STK38L might contribute to the development of certain 
malignancies. STK38 expression is upregulated in carcinomas of the breast and lung 
[257-259], whereas STK38L expression is upregulated in germ cell tumors [260, 261]. 
Additionally, upregulation of both kinases has been observed in ovarian carcinomas [262-
264]. Unlike other malignancies where only one kinase is overexpressed, the 
upregulation of both STK38 and STK38L in ovarian carcinomas indicates that they may 
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have overlapping function in this context. Ultimately, the role of STK38/STK38L in 
promoting tumorigenesis has not been well addressed and, thus, requires further study. 
The ability of both kinases to suppress the development of some malignancies while 
being overexpressed in others suggests that STK38/STK38L have context-specific roles 
promote or prevent cancer. 
 
7. Conclusion 
 The NDR/LATS kinases play a role in numerous biological processes including 
development and tissue homeostasis. Activation of the entire kinase subfamily requires 
phosphorylation of two shared regulatory domains: the activation segment and 
hydrophobic motif. However, the phosphorylation of these domains is regulated by both 
overlapping and non-overlapping mechanisms. Similarly, the NDR/LATS kinases exhibit 
only a handful of shared functions, including the regulation of YAP activity and mitosis. 
Early studies of the NDR/LATS kinases in the context of cancer suggested that they only 
suppress tumorigenesis. However, subsequent work has revealed that the kinases can also 
promote this process. Thus, the NDR/LATS kinases exhibit context-specific functions. 
This additional degree of complexity highlights the need for further characterization of 
the NDR/LATS kinases. 
 
C. Hypothesis and Specific Aims 
 The “aberrantly differentiated endocrine exocrine-like” (ADEX) PDAC subtype is 
characterized by high expression of epithelial differentiation genes and overexpression of 
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oncogenic KRAS [18]. These features are found in a subset of KRAS-mutant PDAC cell 
lines that exhibit a robust dependence on KRAS for survival [31]. KRAS-dependent cells 
frequently harbor KRAS gene amplification and undergo apoptosis following KRAS 
depletion, indicating a state of KRAS oncogene “addiction” or dependency. Indeed, 
KRAS plays a critical role in PDAC initiation and maintenance, making it an attractive 
therapeutic target [29]. However, attempts to develop KRAS-directed therapies for 
clinical use have proven challenging [19-21]. This obstacle has prompted the search for 
alternative therapeutic targets to treat PDAC by identifying synthetic lethal KRAS 
interacting genes that confer a state of non-oncogene dependency [265]. We previously 
identified non-oncogene dependency for the nuclear Dbf2 and LATS1/2-related kinase 
STK38L (also known as NDR2) in the KRAS-mutant SW620 colon cancer cell line 
[266]. Subsequently, we noted that the STK38L and KRAS genes are located in close 
proximity on chromosome 12p11-12, a region frequently amplified in solid tumors, 
including those of the colon and pancreas [267-270]. In the context of cancer, genes are 
frequently amplified because they confer some survival or proliferative advantage. 
Furthermore, tumor cells can become dependent on the expression of these genes, as is 
the case with the MYC and RAS oncogenes [31, 271]. Thus, we hypothesized that 
STK38L promotes cell survival and/or proliferation in ADEX-subtype PDAC cell lines. 
To test our hypothesis, we completed the following aims: 
AIM 1: To determine STK38L gene copy number and mRNA/protein expression in a 
panel of human PDAC cell lines and primary tumors. 
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AIM 2: To determine whether STK38L promotes cell viability and/or proliferation in 
human PDAC cell lines. 
AIM 3: To determine the effect of STK38L expression on overall survival in PDAC 
patients. 
 
D. Significance 
 Effective, targeted therapeutics for PDAC have yet to be identified. This study 
describes gene amplification of, and dependency on, the STK38L kinase gene in subsets 
of human PDAC cell lines and primary tumors. Our findings implicate STK38L as a 
candidate target for an identifiable subset of PDACs. Additionally, this study provides a 
foundation for further characterization of context-dependent STK38L functions in PDAC 
progression. 
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CHAPTER II: MATERIALS AND METHODS 
A. Analysis of Human PDAC Patient Data 
The Pancreatic Adenocarcinoma (PAAD) dataset provided by The Cancer Genome Atlas 
was analyzed using cBioPortal for Cancer Genomics maintained by the Memorial Sloan 
Kettering Cancer Center[272, 273]. This dataset was also analyzed using the UCSC Xena 
Functional Genomics Browser (http://genome.ucsc.edu/) to derive Kaplan-Meier plots of 
associations between selected gene expression levels and patient overall survival [274]. 
 
B. Cell Culture 
Human-derived PDAC cell lines were grown in Roswell Park Memorial Institute (RPMI) 
1640 medium supplemented with 5% fetal bovine serum (FBS), 1 mM sodium pyruvate, 
100 units/ml penicillin, and 100 µg/ml streptomycin. HEK 293T cells were cultured in 
Dulbecco's Modified Eagle Medium (DMEM) supplemented with 10% FBS containing 
tetracycline. Cells were maintained in a humidified incubator at 37°C with 5% CO2. 
 
C. Western Blotting 
Cells were washed in 1X PBS followed by lysis in 1X Laemlli Buffer supplemented with 
Halt Protease and Phosphatase Inhibitor Cocktail (ThermoFisher Inc.). Protein lysates 
were sonicated and normalized for total protein with a Bicinchoninic Acid (BCA) Assay 
Kit (Pierce). Proteins were resolved by SDS-PAGE and then transferred to a 
polyvinylidene fluoride (PVDF) membrane for Western blotting.  Detection of proteins 
was carried out by enhanced chemiluminescence (ECL) using SuperSignal West-Pico or 
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West-Dura (Thermo Fisher Scientific) reagents. Imaging was carried out with a Syngene 
G-Box XT4 system and the GeneSys imaging software. Antibodies used for Western blot 
analyses are provided in Table 1. All antibodies were diluted in 2% w/v BSA in TBS-T. 
Primary Antibodies 
Antibody Source Catalog # Isotype Dilution 
α-Tubulin Invitrogen 13-8000 Mouse 1:1000 
AKT (pan) Cell Signaling Technology 4691 Rabbit 1:1000 
Beclin-1 Cell Signaling Technology 3495 Rabbit 1:1000 
c-Myc Cell Signaling Technology 5605 Rabbit 1:1000 
Cleaved PARP Cell Signaling Technology 5625 Rabbit 1:500 
ERK1/2 Cell Signaling Technology 4695 Rabbit 1:1000 
GAPDH Thermo Fisher Scientific MA5-15738 Mouse 1:10000 
GFP Cell Signaling Technology 2956 Rabbit 1:1000 
HA Bethyl Laboratories A190-108A Rabbit 1:1000 
KRAS Calbiochem OP24 Mouse 1:500 
LATS1 Cell Signaling Technology 3477 Rabbit 1:1000 
LATS2 Cell Signaling Technology 5888 Rabbit 1:500 
LC3A/B Cell Signaling Technology 12741 Rabbit 1:1000 
MEK1/2 Cell Signaling Technology 8727 Rabbit 1:1000 
NDR1/2 (STK38) Santa Cruz Biotechnology sc-271703 Mouse 1:100 
Pan RAS Calbiochem OP40 Mouse 1:500 
p21 Cell Signaling Technology 2947 Rabbit 1:1000 
p62/SQSTM1 Santa Cruz Biotechnology sc-28359 Mouse 1:1000 
pAKT Cell Signaling Technology 4058 Rabbit 1:1000 
pERK1/2 Cell Signaling Technology 4370 Rabbit 1:1000 
pMEK1/2 Cell Signaling Technology 9154 Rabbit 1:1000 
pS6 Cell Signaling Technology 4858 Rabbit 1:1000 
S6 Santa Cruz Biotechnology sc-74459 Mouse 1:1000 
STK38L Alexander Hergovich - UCL [158] Rabbit 1:1000 
YAP Cell Signaling Technology 14074 Rabbit 1:1000 
YAP/TAZ Cell Signaling Technology 8418 Rabbit 1:1000 
Secondary Antibodies (HRP-Linked) 
Antibody Source Catalog # Isotype Dilution 
Anti-Mouse IgG Cell Signaling Technology 7076 N/A 1:5000 
Anti-Rabbit IgG Cell Signaling Technology 7074 N/A 1:5000 
Table 1. Antibodies Used for Western Blot Analyses. 
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D. Immunohistochemistry (IHC)  
STK38L expression was assessed in human PDAC samples by immunohistochemistry. 
Paraffin-embedded tumor microarrays (TMAs) were developed using samples that were 
obtained from consenting patients under IRB approved protocols (Massachusetts General 
Hospital/Dana Farber/Harvard Cancer Center). TMAs were stained using a Leica Bond 
III auto-stainer (Leica Biosystems) according to the manufacturer’s standard protocol. 
Antigen retrieval was carried out with Sodium Citrate (pH 6.0), and a rabbit polyclonal 
antibody directed against STK38Lwas applied to the TMAs at a dilution of 1:250. Tissue 
sections were counter-stained with hematoxylin. Slides were imaged using an Aperio 
ScanScope CS system (Aperio Technologies). 
 
E. Cellular Viability and Quantitation Assays 
Cell viability assays were carried out in 96-well format with Alamar Blue reagent. Cells 
were subjected to siRNA-mediated gene depletion for 72 h and subsequently incubated 
with 50 μg/ml alamarBlue for 1 h at 37°C with 5% CO2. AlamarBlue fluorescence was 
measured with a FLUOstar OPTIMA Microplate Reader (BMG Labtech) at λEx/λEm 
544/590 nm. Cell quantitation assays were carried out in 96-well format. Cells were 
subjected to siRNA-mediated gene depletion for 48 h or treatment with drug diluted in 
0.1% DMSO for 24 h. Cells were fixed with 4% paraformaldehyde in 1X PBS and 
subsequently treated with 5 µg/ml Hoechst 33258 nuclear stain in 1X PBS for 20 min. 
Plates were scanned with a Cytation 3 Imaging Multi-Mode Reader (BioTek) at λEx/λEm 
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377/477 nm. Gen5 Microplate Reader and Imager Software was used to identify and 
count individual nuclei and determine total cell number. 
 
F. siRNA Transfections 
Cells were transfected with siRNAs in 96-, 12-, or 6-well format. Transfections were 
performed in antibiotic-free media using a ratio of 20 pmol siRNA/µl Lipofectamine 
RNAiMax Transfection Reagent (Thermo Fisher Scientific). 
 
G. Quantitative PCR-Based Gene Expression Analyses 
RNA was isolated from cells with an RNeasy Mini Kit (Qiagen Inc.) and subjected to 
reverse transcription using a High Capacity Reverse Transcription Kit (Applied 
Biosystems Inc.). Diluted cDNA was used in TaqMan or SYBR Green-based qPCR 
assays. Relative quantitation determinations were obtained with a StepOne Real-Time 
PCR System (Applied Biosystems). Primer sequences used for SYBR Green-based 
assays are listed in Table 2. 
Gene Direction Sequence 
STK38 
Forward 5’-TTTGGTGAGGTACGGCTTGT-3’ 
Reverse 5’-ACTAGAATGTCACGCTCCGC-3’ 
STK38L 
Forward 5’-GAGAGAGAAACCAGGCAGAAGA-3’ 
Reverse 5’-GTCTGGTCCTTTTGAGCCGT-3’ 
LATS1 
Forward 5’-TGTGGCCTATCATTCTGAGAGT-3’ 
Reverse 5’-TCTGTCCGTTGCTAGGGTGA-3’ 
LATS2 
Forward 5’-ACCCCAAAGTTCGGACCTTAT-3’ 
Reverse 5’-GCATTTGCCGGTTCACTTCTG-3’ 
GAPDH 
Forward 5’-GAGTCAACGGATTTGGTCGT-3’ 
Reverse 5’-TTGATTTTGGAGGGATCTCG-3’ 
Table 2. RT-qPCR Primer Sequences. 
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H. Gene Copy Number Assay 
Genomic DNA was isolated from cells with a QIAamp DNA Mini Kit (Qiagen Inc). 
STK38L gene copy number was assessed with a TaqMan Copy Number Assay Kit 
(Applied Biosystems). Recommended/validated probes for STK38L and the reference 
gene RPPH1/RNaseP were used in this assay. Relative quantitation determinations were 
obtained with a StepOne Real-Time PCR System (Applied Biosystems). 
 
I. Lentiviral Work 
Lentiviral particles were generated using a three-plasmid system as described previously 
[275, 276]. Briefly, 293T cells were transfected with the desired lentiviral expression 
vector, the lentiviral packaging vector psPAX2 (gift from Didier Trono; Addgene 
plasmid #12260), and the lentiviral envelope vector pMD2.G-VSV-G (gift from Didier 
Trono; Addgene plasmid #12259). Lentivirus production was induced the next day by 
treatment with DMEM supplemented with 30% FBS. The viral supernatant was collected 
24 h post-induction and syringe-filtered to remove any potential cell contaminants. Target 
cells were subsequently spin-infected with lentiviral particles in the presence of 8 µg/ml 
polybrene at 1200xg for 1 h. Selection of infected cells was carried out by treatment with 
1 µg/ml puromycin. 
 
  
69
J. 2D Clonogenic Assay 
PDAC cells transduced with shRNA expression plasmids were seeded on a 6-well plate 
at a density of 1000 cells/well and maintained for 10 days. Colonies were fixed with 4% 
paraformaldehyde in 1X PBS and subsequently stained overnight with Geimsa dye 
(Ricca Chemical Company) diluted 1:50 in 1X PBS. Images of each well were captured 
with a Bio-Rad ChemiDoc XRS+ using the Image LabTM Software. 
 
K. 3D Clonogenic Assay 
PDAC cells transduced with shRNA expression plasmids were seeded on an 8-well 
chamber slide (Lab-Tek) coated with MatrigelTM (Corning) and maintained for 6 days as 
previously described [277]. Representative images of each well were captured by bright-
field microscopy and subsequently analyzed using CellProfiler software to determine 
average colony size [278]. For immunofluorescence imaging, colonies were fixed with 
4% paraformaldehyde in 1X PBS. Colonies were sequentially incubated with Alexa594-
conjugated phalloidin to stain actin filaments (Thermo Fisher Scientific) and Hoechst 
33256 dye to stain nuclear DNA. Image acquisition was performed with a Cytation 3 
Imaging Multi-Mode Reader (BioTek) at 10X magnification. 
 
L. Cell Lines, Reagents, and Plasmid Constructs 
Cell lines were obtained from commercial sources and have been characterized 
previously [31]. Additional information on these cell lines, including core genetic 
alterations and patient characteristics, is provided in Table 3. Anisomycin was purchased 
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from Sigma-Aldrich Inc. Endoribonuclease-prepared siRNAs directed against STK38L 
were purchased from Sigma-Aldrich. Dicer substrate siRNAs (dsRNAs) directed against 
STK38L were purchased from Integrated DNA Technologies (IDT) Inc. SMARTpool 
siRNAs directed against LATS1, LATS2, and CDKN1A/p21 were purchased from 
Dharmacon Inc. Target sequences for all siRNAs are listed in Table 4. For rescue 
experiments, HA-STK38L-PIF WT and HA-STK38L-PIF K119R were PCR amplified 
from pcDNA3 and cloned into the pDONR223 Gateway donor vector (Invitrogen). 
Primer sequences are listed in Table 5. Genes were subsequently transferred to pLEX307 
lentiviral-based expression plasmid (gift from David Root; Addgene plasmid #41392) by 
Gateway cloning. Lentiviral pLKO.1 shRNA expression vectors for luciferase and 
STK38L were obtained from the RNAi Consortium (TRC – Broad Institute of 
Harvard/MIT). Lentiviral pLKO.1 shRNA expression vectors for YAP and TAZ have 
been described previously [189, 279]. The target sequences for all shRNAs are listed in 
Table 6. KRAS 4A/4B expression constructs are in the pLenti-pGK vector backbone and 
have been described previously [266]. 3xFLAG-TAZ WT/4SA expression constructs are 
in the pLVX-Tight-puro vector backbone and have been described previously [279]. 
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 Genetic Alterations Patient Characteristics 
Cell Line KRAS CDKN2A TP53 SMAD4 Age Sex Ethnicity 
DAN-G G12V HD 993+16del.38 MUT - - - 
YAPC G12V HD H179R R515fs*22 43 Male Japanese 
HuP-T4 G12V HD I225T - 60 Male Japanese 
Panc04.03 G12D INS G245S - 70 Male Caucasian 
PaTu 8902 G12V - C176S - 44 Female - 
SUIT-2 G12D HD R273H - 73 Male Japanese 
PaTu 8988t G12D - R282W - 64 Female - 
PANC1 G12V HD R273H WT 56 Male Caucasian 
SW 1990 G12V HD P191del WT 56 Male Caucasian 
HuP-T3 G12R HD R282W WT 66 Male Japanese 
MIA PaCa-2 G12C HD R248W WT 65 Male Caucasian 
KP-1N G12D - - WT 69 Male Japanese 
BxPC-3 WT HD Y220C HD 61 Female - 
Table 3. Pancreatic Cell Lines.  HD: homozygous deletions; INS: insertion; Data were compiled from 
multiple sources [280-292]. Note: Information for some cell lines could not be found (indicated by “-”). 
 
Gene siRNA Target Sequence 
STK38L 
#1 5’-CUGGAGUUAAUAGAGUGAUUCAC-3’ 
#2 5’-CACGCUCGCAAAGAAACAGAGUU-3’ 
CDKN2A/p21 
#1 5'-CGACUGUGAUGCGCUAAUG-3' 
#2 5'-CCUAAUCCGCCCACAGGAA-3' 
#3 5'-CGUCAGAACCCAUGCGGCA-3' 
#4 5'-AGACCAGCAUGACAGAUUU-3' 
LATS1 
#1 5’-GGUGAAGUCUGUCUAGCAA-3’ 
#2 5’-UAGCAUGGAUUUCAGUAAU-3’ 
#3 5’-GGUAGUUCGUCUAUAUUAU-3’ 
#4 5’-GAAUGGUACUGGACAAACU-3’ 
LATS2 
#1 5’-GCACGCAUUUUACGAAUUC-3’ 
#2 5’-ACACUCACCUCGCCCAAUA-3’ 
#3 5’-AAUCAGAUAUUCCUUGUUG-3’ 
#4 5’-GAAGUGAACCGGCAAAUGC-3’ 
Table 4. siRNA Target Sequences. 
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Primer Sequence 
Forward 
5’-GGGGACAAGTTTGTACAAAAAAGCAGGC-
TTCGATATCACCATGGCCTACCCCTACG-3’ 
Reverse 
5’-GGGGACCACTTTGTACAAGAAAGCTGGGT-
CGGATCCTCACCAGTCGGCGATGTAGT-3’ 
Table 5. PCR Primers for Gateway Cloning of HA-STK38L-PIF WT and HA-STK38L-PIF K119R. 
 
Gene Target Sequence 
STK38L 5’-GAAGAAGGATTAGCAGATGAA-3’ 
YAP 5’-AAGCTTTGAGTTCTGACATCC-3’ 
TAZ 5’-GCGATGAATCAGCCTCTGAAT-3’ 
Table 6. Target Sequences of Lentiviral pLKO.1 shRNA Expression Vectors. 
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CHAPTER III: RESULTS 
A. KRAS and STK38L copy number gains and expression levels in human PDAC 
 To assess the prevalence of STK38L gene copy number alterations in human 
PDAC, we analyzed the pancreatic adenocarcinoma (PAAD) dataset from The Cancer 
Genome Atlas (TCGA), which contains information on 149 human PDACs (Fig. 5A). 
Consistent with previous studies, there is over a 90% frequency of KRAS mutations in the 
TCGA PDAC cohort.  STK38L gene amplification was observed in 2.7% percent of 
tumors. STK38L copy number gains were concordant with KRAS gene amplification. 
However, two tumors exhibited KRAS amplification alone. Using this same data set we 
performed a linear regression analysis and observed a positive correlation (r = 0.9616; p 
< 0.0001) between absolute KRAS and STK38L gene copy number values (Fig. 5B). We 
also observed a positive correlation between STK38L and KRAS mRNA expression (r = 
0.5232; p < 0.0001) (Fig. 5C). In contrast, we failed to observe a significant correlation 
between expression levels of the STK38 isoform and KRAS (r = 0.0693; p = 0.4011) (Fig. 
5D). Next, we performed correlation analyses of expression levels for other genes located 
within the chromosome 12p11-12 amplicon. With the exception of MED21, KRAS and 
STK38L expression levels were the most correlated of all the genes tested (Fig. 6). These 
findings indicate that the correlation of KRAS and STK38L expression levels are not 
simply due to proximal genomic context and could be due to transcriptional co-
regulation. 
 We subsequently assessed STK38L protein levels in a panel of twelve human 
PDAC-derived cell lines by Western blotting (Fig. 7A). STK38L protein expression 
  
74
varied considerably across the panel of cell lines. We also assessed KRAS protein levels 
in the cell line panel and observed a similar degree of variation, with some cell lines 
expressing high levels of KRAS protein, as previously reported [31]. Notably, we 
observed a significant correlation between STK38L and KRAS protein levels as 
determined by densitometric analysis (r = 0.8112, p = 0.0014) (Fig. 7B). In summary, 
STK38L and KRAS gene copy number, mRNA and protein levels are tightly correlated 
in human PDAC and tumor-derived cell lines. 
 
Figure 5. STK38L and KRAS expression levels correlate in primary PDACs. A. Oncoprint summary of 
KRAS, STK38, and STK38L genomic alterations in 149 primary PDACs. Individual genes are represented 
by rows, and individual tumors are represented by columns. B. Correlation analysis of STK38L and KRAS 
relative linear copy number values. C. Correlation analysis of STK38L and KRAS mRNA expression 
(RNA-Seq V2 RSEM). D. Correlation analysis of STK38 and KRAS mRNA expression (RNA-Seq V2 
RSEM).  
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Figure 6. Expression of KRAS does not always correlate with other co-amplified genes. Correlation 
analysis of 12p11-12p12 amplicon genes and KRAS mRNA expression (RNA-Seq V2 RSEM). 
 To assess whether STK38L expression is elevated in primary PDACs, we 
analyzed a series of human PDAC tissue microarray (TMA) slides by 
immunohistochemistry (Fig. 7C). Consistent with our observations in PDAC cell lines, 
STK38L protein levels varied significantly across the primary tumor cohort. A subset of 
tumors was found to express high levels of STK38L protein. In contrast, STK38L 
expression was weak or barely detectable in another subset of tumors. We conclude that 
STK38L protein expression levels follow a variable spectrum both in cell lines and in 
primary PDACs. 
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Figure 7. STK38L and KRAS expression levels correlate in PDAC-derived cell lines. A. Western blot 
of STK38L and KRAS protein levels in a panel of human PDAC cell lines. Data are representative of two 
independent experiments. B. Correlation analysis of STK38L and KRAS protein expression in human-
derived PDAC cell lines. C. Representative images of STK38L protein expression (brown stain) in human 
PDAC samples. Cells are counterstained with haematoxylin (blue). 
 
B. STK38L depletion promotes cell death in a subset of human-derived PDAC cell 
lines 
 To determine the role of STK38L in promoting cell proliferation and survival in 
PDAC cell lines, we performed a series of functional experiments using RNAi against 
STK38L. Firstly, we used pooled endoribonuclease-prepared small interfering RNAs 
(esiRNAs), which have been used effectively in genome-wide RNAi screens [293]. 
Transfection of STK38L-directed esiRNAs was performed to determine effects on 
relative cell proliferation and viability (Fig. 8A). STK38L depletion caused a spectrum of 
growth inhibitory effects in a panel of twelve well-characterized PDAC cell lines. Of 
note, a subset of cell lines was highly sensitive to the growth inhibitory effects of 
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STK38L depletion. STK38L knockdown was validated in the most and least sensitive 
cell lines, DAN-G and KP-1N respectively, by qPCR (Fig. 8B). We observed a 
significant reduction in STK38L mRNA levels in both cell lines following esiRNA 
transfection. Importantly, the STK38L-directed esiRNAs did not display off-target effects 
on related STK38, LATS1, and LATS2 mRNA expression (Fig. 8B). On the contrary, 
LATS1 and LATS2 levels were increased following STK38L depletion. 
 
Figure 8. STK38L promotes cell survival in a subset of PDAC cell lines. A. Assessment of relative cell 
viability by Alamar Blue assay in a panel of human PDAC cell lines 72 h post-transfection with pooled 
esiRNAs directed against STK38L. Data are represented as the mean of six technical replicates +/- SEM. B. 
RT-qPCR analysis of relative NDR/LATS kinase mRNA levels for DAN-G and KP-1N cells 24 h post-
transfection with pooled esiRNAs directed against STK38L. Data are the mean of three technical replicates 
+/- SEM. Statistical significance was assessed by Student’s t-test (*** - p < 0.001; **** - p < 0.0001). C. 
Western blots showing levels of cleaved PARP as an indicator of apoptosis in a panel of human PDAC cell 
lines 48 h post-transfection with individual siRNA sequences (#1 and #2) directed against STK38L. 
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GAPDH serves as a gel loading control. Note: Different exposure times were used for individual panels. 
All data are representative of two or three independent experiments. 
 Next, we determined the effect of STK38L depletion on levels of cleaved 
poly(ADP-ribose) polymerase (PARP), which is a marker of caspase 3-mediated 
apoptosis (Fig. 8C). For these assays, we used two STK38L-selective siRNA 
oligonucleotides. These siRNAs did not significantly affect STK38 protein levels (Fig. 
8C). The three cell lines that were most sensitive to the growth inhibitory effects of 
STK38L-directed esiRNAs, DAN-G, YAPC, and HuP-T4, had the most significantly 
elevated cleaved PARP levels in response to STK38L depletion. Although Panc 04.03 
cells were strongly growth inhibited following esiSTK38L introduction, we did not 
observe any PARP cleavage in these cells using single siRNAs. The nine remaining cell 
lines were moderately responsive or unresponsive to STK38L depletion in terms of 
PARP cleavage/apoptosis. We validated these contrasting effects on PARP cleavage 
using esiRNA-mediated depletion of STK38L in DAN-G and KP-1N cells (Fig. 9A). To 
rule out the possibility that KP-1N cells are generally resistant to apoptosis, we treated 
the DAN-G and KP-1N cells with the apoptosis-inducing agent anisomycin, and showed 
comparable effects in both cell lines (Fig. 9B). Taken together, these findings suggest that 
selective knockdown of STK38L elicits a spectrum of antiproliferative effects in human 
PDAC cell lines, with a subset of cell lines undergoing PARP-cleavage associated 
apoptotic cell death. 
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Figure 9. KP-1N cells are insensitive to STK38L depletion. A. Western blot analysis of cell death 
induction in DAN-G and KP-1N cells 48 h post-transfection with pooled esiRNAs directed against 
STK38L. GAPDH serves as a gel loading control B. Dose-response curve of DAN-G and KP-1N cells 
treated with anisomycin. Data are the mean of five technical replicates +/- SEM at the indicated drug 
concentrations. 
 As oncogene dependency is often associated with copy number gain, we assessed 
STK38L gene copy number via genomic qPCR in the same panel of PDAC cell lines 
previously characterized (Fig. 10A). We observed varying STK38L gene copy number 
gains across the cell line panel. However, gene copy number failed to correlate (r = 
0.4373; p = 0.1198) with the antiproliferative effects of STK38L depletion (Fig. 10B). 
We subsequently assessed STK38L mRNA transcript levels in the same cell line panel by 
RT-qPCR (Fig. 10C). We observed a positive correlation (r = 0.8339; p = 0.0007) 
between STK38L transcript levels and STK38L dependency (Fig. 10D). However, this 
analysis was skewed by one sample (DAN-G). Two of the three STK38L-dependent cell 
lines, DAN-G and YAPC, had significantly elevated STK38L protein levels compared to 
cell lines that were not STK38L-dependent (Fig. 7A). Taken together, these findings 
suggest that high STK38L mRNA and protein expression are associated with, though not 
entirely predictive of, STK38L dependency in PDAC cell lines. STK38L gene copy 
number gains can be found in a subset of cell lines, but do not correlate significantly with 
STK38L dependency. 
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Figure 10. Analysis of STK38L gene copy number and mRNA transcript levels in human PDAC cell 
lines. A. Analysis of STK38L gene copy number in a panel of human PDAC cell lines. Shown are the 
normalized averages of four technical replicates +/- SEM. B. Correlation analysis of STK38L dependency 
(calculated as the inverse of percent viability following esiSTK38L transfection) and gene copy number. C. 
RT-qPCR analysis of STK38L mRNA levels in a panel of human PDAC cell lines. Shown are the averages 
of three technical replicates +/- SEM. D. Correlation analysis of STK38L dependency and mRNA 
expression. 
 
C. The kinase activity of STK38L is necessary to promote cell survival 
 To validate the on-target specificity of STK38L-directed siRNA oligonucleotides, 
we performed a series of rescue experiments using a constitutively-activated variant of 
STK38L (STK38L-PIF), which contains a PRK2 hydrophobic motif at the C-terminus 
[144, 203]. This motif promotes STK38L kinase autophosphorylation independent of 
hMOB1A/B and MST1/2/3 rendering both sets of proteins dispensable for STK38L 
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activation. We established DAN-G cells stably expressing GFP, HA-STK38L-PIF WT, 
or HA-STK38L-PIF K119R (kinase-dead variant) (Fig. 11A). We depleted endogenous 
STK38L in the stable DAN-G cell lines by transfection with a siRNA directed against the 
STK38L 3’-UTR (siSTK38L #1), which does not target the exogenous STK38L mRNA. 
We quantified the total number of cells remaining following STK38L depletion by 
automated DAPI-stained nuclei counting (Fig. 11B). Cells expressing GFP or HA-
STK38L-PIF K119R showed reduced cell numbers following STK38L depletion. 
Comparatively, cells expressing HA-STK38L-PIF WT showed a significantly weaker 
reduction in cell number following STK38L depletion (Fig. 11B). Under similar 
experimental conditions, we analyzed changes in cleaved PARP by Western blot (Fig. 
11C). DAN-G cells expressing GFP or HA-STK38L-PIF K119R exhibited nearly a four-
fold increase in cleaved PARP when compared to the control treatment. However, cells 
expressing HA-STK38L-PIF WT exhibited no change. As an additional control, we used 
a siRNA directed against the coding sequence of STK38L (siSTK38L #2), which targets 
both endogenous and exogenous STK38L expression. This siRNA had similar 
antiproliferative effects in GFP, HA-STK38L-PIF WT and HA-STK38L-PIF K119R 
expressing stable cell lines (Fig. 12). Taken together, these findings demonstrate that the 
siSTK38L effects on cell viability are on-target and that the kinase activity of STK38L is 
necessary for cell survival in DAN-G cells. 
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Figure 11. STK38L kinase activity is necessary to promote the survival of DAN-G cells. A. Western 
blot of DAN-G cells stably expressing GFP, HA-STK38L-PIF WT, or HA-STK38L-PIF K119R. GAPDH 
serves as a gel loading control. B. Cell number quantitation of DAN-G cells stably expressing GFP, HA-
STK38L-PIF WT, or HA-STK38L-PIF K119R 48 h post-transfection with a siRNA directed against the 3’-
UTR of STK38L at 6 nM final concentration. Data are the mean of five technical replicates +/- SEM. 
Statistical significance was assessed by one-way ANOVA with Tukey’s test for post-hoc validation (** - p 
< 0.01; *** - p < 0.001). C. Western blot analysis of cleaved PARP levels following siRNA-mediated 
depletion of STK38L in DAN-G cells stably expressing GFP, HA-STK38L-PIF WT, or HA-STK38L-PIF 
K119R. GAPDH serves as a gel loading control. Protein band (cleaved PARP to GAPDH ratio) 
densitometric quantification values are indicated at the bottom. Note: The cleaved PARP/GAPDH ratio was 
normalized internally for each cell line. 
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Figure 12. Loss of endogenous and exogenous STK38L elicits an antiproliferative effect in DAN-G 
cells.Quantitation of DAN-G cells stably expressing GFP, HA-STK38L-PIF WT, or HA-STK38L-PIF 
K119R 48 h post-transfection with a siRNA directed against the coding sequence of STK38L. Data are the 
mean of five technical replicates +/- SEM. Statistical significance was assessed by one-way ANOVA with 
Tukey’s test for post-hoc validation (** - p < 0.01). 
 
D. STK38L depletion causes reduced clonogenic growth in DAN-G cells 
 To further validate the role of STK38L in promoting cell proliferation and 
survival, we performed a series of clonogenic assays. First, we stably depleted STK38L 
in DAN-G and PANC1 cells by lentiviral shRNA transduction and verified selective 
STK38L protein knockdown (Fig. 13A). STK38L-depleted DAN-G cells formed 
significantly fewer colonies compared to shLuciferase (shLUC)-expressing cells in 2D 
culture (Fig. 13B). Furthermore, the colonies formed by STK38L-depleted DAN-G cells 
were substantially smaller in size. STK38L-depleted PANC1 cells also formed smaller 
colonies compared to control shLUC-expressing cells. However, the effects of STK38L 
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depletion were relatively modest in PANC1 cells compared to DAN-G cells. Next, we 
repeated this experiment in 3D format using MatrigelTM. This assay provides a more 
physiologically relevant microenvironment that incorporates tumor cell-extracellular 
matrix (ECM) interactions. When grown in MatrigelTM, STK38L-depleted DAN-G cells 
formed substantially smaller colonies compared to shLUC-expressing cells, as 
demonstrated by colony nuclear DNA and actin staining (Fig. 13C). STK38L-depleted 
PANC1 cells also formed smaller colonies compared to control shLUC-expressing cells. 
However, the effect of STK38L depletion was relatively modest in PANC1 cells 
compared to DAN-G cells. Automated computer-assisted quantitation of colony size 
validated these results for shLUC- and shSTK38L-expressing DAN-G and PANC1 cells 
(Fig. 13D). STK38L depletion caused a 68% reduction in the size of colonies formed by 
DAN-G cells but only a 28% reduction in the size of colonies formed by PANC1 cells. In 
summary, STK38L depletion causes substantially reduced clonogenic growth in DAN-G 
cells but only has a modest effect in PANC1 cells. 
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Figure 13. STK38L promotes clonogenic growth of DAN-G cells in 3D culture. A. Western blot 
analysis of stable DAN-G and PANC1 cell lines expressing shRNAs for luciferase (shLUC) or STK38L 
(shSTK38L). GAPDH serves as a gel loading control. B. Representative images of colonies formed by 
DAN-G and PANC1 cells 11 days post-transduction with lentiviral shRNA expression vectors directed 
against luciferase or STK38L. C. Representative images of colonies formed by DAN-G and PANC1 cells 
in MatrigelTM 7 days post-transduction with lentiviral shRNA expression vectors directed against luciferase 
or STK38L. Phalloidin-stained actin is visualized in red and DAPI-stained nuclear DNA in blue. Scale bar 
= 20 µm. Data are representative of two independent experiments. D. Average colony size of DAN-G and 
PANC1 cells grown in MatrigelTM and imaged 7-days post-transduction with lentiviral shRNA expression 
vectors directed against luciferase or STK38L. Statistical significance was assessed by Student’s t-test (* - 
p < 0.05; **** - p < 0.0001). 
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E. STK38L depletion causes cell death via induction of LATS2 expression 
 To understand mechanisms underlying STK38L dependency in PDAC cell lines, 
we characterized the effects of STK38L depletion on expression levels of key proteins in 
KRAS and general tumor-associated signaling pathways including p21, MYC, MAPK, 
PI3K, and autophagy (Fig. 14A). STK38L depletion caused increased ERK and 
ribosomal S6 protein phosphorylation in some cell lines, including DAN-G. We also 
noted that LC3-II levels were moderately increased in a four cell lines following STK38L 
depletion, indicating a possible block in autophagy flux. This is concordant with previous 
reports of NDR kinase regulation of autophagosome formation [220]. However, this 
effect of STK38L depletion on LC3-II levels was not generalizable across all eight 
PDAC cell lines tested and did not correlate with PARP cleavage-associated cell death. In 
six of the cell lines tested, particularly STK38L-dependent cell lines, STK38L depletion 
led to increased protein expression levels of p21, consistent with previous reports [151, 
211, 212]. As p21 has been implicated in the induction of apoptosis in some contexts 
[294, 295], we tested a role for p21 in STK38L-regulated cell survival. To that end, we 
concomitantly depleted p21 and STK38L in DAN-G cells using combinations of siRNA 
oligonucleotides (Fig. 14B). Depletion of p21 alone had no effect on apoptotic cell death 
induction, as assessed by PARP cleavage. On the contrary, combined depletion of 
STK38L and p21 caused increased PARP cleavage compared to STK38L depletion 
alone. We also depleted p21 prior to STK38L depletion and, again, observed no 
significant effect on apoptosis, as determined by quantitating the number of remaining 
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cells (Fig. 14C). Therefore, we conclude that induction of p21 expression does not 
contribute to cytotoxicity following STK38L depletion. 
 
Figure 14. STK38L depletion increases p21 protein abundance. A. Western blot analysis of human 
PDAC cell lines 48 h post-transfection with two siRNAs directed against STK38L (siSTK38L #1 and #2) 
in combination at 10 nM final concentration. GAPDH is used as a gel loading control. Note: Different 
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exposure times were used for individual panels. B. Western blot analysis of DAN-G cells 48 h post-
transfection with pooled siRNAs directed against CDKN1A/p21 (25 nM) and STK38L (10 nM). GAPDH is 
used as a gel loading control. C. Quantitation of DAN-G cells 72 h post-transfection with siRNAs directed 
against CDKN1A/p21 and STK38L alone or in combination. Data are the mean of five technical replicates 
+/- SEM. Statistical significance was assessed by Student’s t-test (*** - p < 0.001). 
 To further validate the on-target effects of siRNA-mediated STK38L depletion, 
we determined mRNA expression levels of related STK38, LATS1, and LATS2 kinase 
genes. STK38L depletion caused increased mRNA expression of LATS2 but had no 
effects on STK38 or LATS1 mRNA transcript levels in DAN-G, YAPC, and KP-1N cells 
(Fig. 15A). These effects of STK38L depletion on LATS1/2 and STK38/STK38L mRNA 
expression were consistent with changes in protein expression levels as assessed by 
Western blotting (Fig. 15B). Depletion of STK38L caused reduced expression of LATS1 
in DAN-G cells but had no effect in KP-1N cells. In contrast, STK38L depletion caused 
increased protein levels of LATS2 in both cell lines. The effect of STK38L depletion on 
LATS2 mRNA and protein expression was more robust in DAN-G cells compared to KP-
1N cells. Reciprocal control of LATS1/2 and STK38/STK38L expression levels has been 
documented in previous reports [179, 180, 296]. However, our studies represent the first 
report of STK38L-mediated control of LATS2 expression. 
 LATS2 can promote apoptosis in some contexts [198, 218, 297]. Thus, we 
hypothesized that induction of LATS2 expression contributes to cytotoxicity following 
STK38L depletion. To test this, we depleted STK38L either alone or in combination with 
either LATS1 or LATS2 depletion in DAN-G cells. Depletion of either LATS1 or 
LATS2 had no significant effect on cell proliferation and viability (Fig. 15C). STK38L 
depletion caused reduced cell proliferation and viability in DAN-G cells. This effect did 
not change significantly with co-depletion of LATS1. In contrast, co-depletion of LATS2 
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with STK38L caused a 13% increase in cell proliferation (Fig. 15C). We confirmed on-
target effects of siRNA co-transfections on LATS1/2 and STK38/STK38L protein 
expression levels by Western blotting (Fig. 15D). Taken together, we conclude that cell 
death and cytotoxicity associated with STK38L depletion in DAN-G cells occurs, in part, 
via induction of LATS2 expression. 
 
Figure 15. Increased LATS2 expression following STK38L depletion contributes to cytotoxicity. A. 
RT-qPCR analysis of relative mRNA transcript levels in DAN-G, YAPC, and KP-1N cells 24 h post-
transfection with a single siRNA directed against STK38L (siSTK38L #2). Data are the mean of three 
technical replicates +/- SEM. Statistical significance was assessed by Student’s t-test (* - p < 0.05; ** - p < 
0.01; *** - p < 0.001; **** - p < 0.0001). B. Western blot analysis of DAN-G and KP-1N cells 48 h post-
transfection with siSTK38L #2. GAPDH serves as a gel loading control. C. Quantitation of DAN-G cell 
numbers 48 h post-transfection with siRNAs directed against LATS1 or LATS2 plus control siRNA or in 
combination with siSTK38L. Data are the mean of 15 technical replicates +/- SEM and are representative 
of two independent experiments. Statistical significance was assessed by one-way ANOVA with Dunnett’s 
test for post-hoc validation (** - p <0.01). D. Western blot analysis of DAN-G cells 48 h post-transfection 
with pooled siRNAs directed against LATS1 (L1) and LATS2 (L2). GAPDH serves as a gel loading 
control. 
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 YAP and TAZ interact with the TEAD family of transcription factors to drive the 
expression of genes that promote cell survival and proliferation [99]. LATS2 inhibits 
YAP and TAZ through a series of direct phosphorylations that result in the cytoplasmic 
retention and subsequent degradation of both proteins [99]. Consistent with this finding, 
we observed decreased YAP and TAZ protein levels in DAN-G cells following STK38L 
depletion (Fig. 15B). Thus, we hypothesized that reduced YAP/TAZ expression could 
confer antiproliferative effects in DAN-G cells, which are sensitive to STK38L depletion. 
To test this hypothesis, we depleted YAP and TAZ individually by lentiviral shRNA 
transduction in DAN-G cells. We then quantified the total number of remaining cells by 
automated DAPI-stained nuclei counting (Fig. 16A). Reductions in total cell number 
were observed following depletion of YAP or TAZ relative to the luciferase control. 
However, this effect was more robust following TAZ depletion. To determine whether 
the reductions in total cell number were due to apoptotic cell death, we analyzed changes 
in cleaved PARP under the same experimental conditions (Fig. 16B). Cleaved PARP was 
observed in TAZ-depleted cells but not YAP-depleted cells. This observation indicates 
that loss of TAZ induces apoptosis in DAN-G cells whereas loss of YAP inhibits cell 
proliferation. 
 To determine whether the loss of viability in DAN-G cells observed following 
STK38L depletion was due to a decrease in TAZ protein levels, we performed a rescue 
experiment using a mutant form of TAZ (4SA: S66A, S89A, S117A, and S311A) that 
cannot be phosphorylated by LATS2 [186]. We established DAN-G cells stably 
expressing an empty vector Control, 3xFLAG-TAZ WT, or 3xFLAG-TAZ 4SA (Fig. 
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16C). Exogenous levels of TAZ WT were notably lower than TAZ 4SA, possibly due to 
compensatory regulation by the Hippo pathway. We depleted STK38L in the stable 
DAN-G cell lines by transfection with a pool of siRNAs and quantified the total number 
of cells remaining by automated DAPI-stained nuclei counting (Fig. 16D). Cells 
expressing the empty vector Control or TAZ WT showed significantly reduced cell 
numbers following STK38L depletion (73% and 67% respectively). Comparatively, cells 
expressing TAZ 4SA showed a significantly weaker reduction in cell number following 
STK38L depletion (39%) (Fig. 16D). Collectively, these findings suggest the cytotoxic 
effect associated with STK38L depletion is due, in part, to LATS2-mediated degradation 
of TAZ. 
 
Figure 16. Loss of TAZ induces apoptosis in DAN-G cells. A. Quantitation of DAN-G cell numbers 72 h 
post-transduction with shRNAs directed against luciferase (shLUC), YAP (shYAP), or TAZ (shTAZ). Data 
are the mean of twelve technical replicates +/- SEM and are representative of two independent experiments. 
Statistical significance was assessed by one-way ANOVA with Dunnett’s test for post-hoc validation (**** 
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- p < 0.0001). B. Western blot analysis of DAN-G cells 72 h post-transduction with lentiviral shRNA 
expression vectors directed against luciferase, YAP, or TAZ. GAPDH serves as a loading control. Data are 
representative of two independent experiments. C. Western blot analysis of DAN-G cells stably expressing 
an empty vector Control, 3xFLAG-TAZ WT, or 3xFLAG-TAZ 4SA. Both endogenous (lower band) and 
3xFLAG-tagged exogenous (upper band) TAZ are shown. GAPDH serves as a gel loading control. D. 
Quantitation of DAN-G cells stably expressing an empty vector Control, 3xFLAG-TAZ WT, or 3xFLAG-
TAZ 4SA 48 h post-transfection with a siRNAs directed against STK38L at 25 nM final concentration. 
Data are the mean of eighteen technical replicates +/- SEM and are representative of two independent 
experiments. Statistical significance was assessed by one-way ANOVA with Dunnett’s test for post-hoc 
validation (*** - p < 0.001). 
 
F. High STK38L mRNA expression is associated poor prognosis in PDAC patients 
 To determine whether STK38L expression correlates with clinical outcome in 
PDAC patients, we performed Kaplan-Meier analyses using PDAC RNA-seq derived 
gene expression data in The Cancer Genome Atlas (TCGA-PAAD dataset) (Fig. 17) 
[298]. We found that high STK38L mRNA expression associates with a significantly 
lower overall patient survival when compared to low STK38L expression (hazard ratio: 
1.652, 95% confidence interval: 1.096-2.490, p = 0.0165). Of note, expression of 
LATS1/2 and STK38 kinase genes did not correlate with survival. As STK38L and KRAS 
are co-amplified in a subset of PDACs, we examined whether there is a relationship 
between KRAS expression and survival. We found that high KRAS expression was indeed 
associated with poor survival (hazard ratio: 1.766, 95% confidence interval: 1.174-2.656, 
p = 0.0063) (Fig. 18). To rule out the possibility that the lower overall survival associated 
with STK38L expression is a passenger effect, we analyzed the expression of other genes 
located in the chromosome 12p11-12p12 amplicon. Of seven genes analyzed (RASSF8, 
BHLHE41, SSPN, ITPR2, FGFR1OP2, TM7SF3 and MED21), none associated 
significantly with patient outcome (Fig. 18). Therefore, we conclude that elevated 
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STK38L and KRAS mRNA expression levels are specifically associated with poor patient 
outcome in PDAC cases. 
 
Figure 17. High STK38L expression is associated with decreased overall survival in PDAC patients. 
Kaplan-Meier analysis of PDAC patient survival data showing the effects of indicated gene expression on 
overall survival. Statistical significance was assessed by Mantel–Cox test (log-rank p-value). 
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Figure 18. High KRAS expression is associated with decreased overall survival in PDAC patients. 
Kaplan-Meier analysis of PDAC patient data showing the effect of KRAS expression, as well as the 
expression of other genes in the 12p11-12p12 chromosomal region, on overall survival. Statistical 
significance was assessed by Mantel–Cox test (log-rank p-value). 
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CHAPTER IV: DISCUSSION 
A. STK38L as a Potential Therapeutic Target for PDAC 
 The inter- and intratumoral molecular heterogeneity of PDAC has confounded 
efforts to identify generally efficacious therapeutic agents. Furthermore, oncogenic 
KRAS, which is a central driver of PDAC progression, remains “undruggable”. It is 
plausible that molecular subtype-selective targeted therapeutic agents could be effective 
in managing disease outcome by allowing for a more tailored and precise regimen. In this 
study, we identified STK38L gene amplification in a subset of human PDACs. 
Importantly, high STK38L expression is correlated with poor patient survival. Genetic 
STK38L depletion causes the selective killing of a subset of human PDAC cell lines, 
many of which have molecular hallmarks of the ADEX tumor subtype [18]. Therefore, 
we implicate STK38L as a candidate therapeutic target for a subset of ADEX-like 
PDACs. 
 
B. Context-Dependent Functions of STK38L in Cancer 
 Previous studies have suggested that STK38 and STK38L function as tumor 
suppressors in some contexts. Genetic ablation of STK38 predisposes mice to the 
development of T-cell lymphoma [179]. However, nearly all tumors derived from these 
mice exhibit a loss of STK38L expression, suggesting that both kinases function 
redundantly as tumor suppressors in this context. Subsequent work revealed that T cell-
specific deletion of either STK38 or STK38L alone does not result in T cell lymphoma 
[192]. Rather, both genes must be deleted to cause the disease. STK38L-null mice do not 
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develop T-cell lymphoma. Furthermore, STK38 is the most abundantly expressed 
isoform in organs of the immune system, like the spleen and thymus, whereas STK38L is 
more predominantly expressed in the gastrointestinal tract [144, 179]. Taken together, 
these findings indicate that potential tumor suppressor function of STK38L as it relates to 
the development of T-cell lymphoma might be of little relevance. 
 STK38L has also been implicated as a tumor suppressor in the colon, as 
conditional deletion of the STK38L gene in the intestinal epithelium of STK38-null mice 
enhances azoxymethane/dextran sodium sulfate-induced carcinogenesis [191]. This 
phenotype results from the deregulation of YAP. Parallel work carried out in vitro 
revealed that STK38L directly phosphorylates YAP at multiple sites. Furthermore, 
overexpression of STK38L in colon cancer cell lines promotes the cytoplasmic retention 
of YAP and impairs proliferation. In concordance with these observations, deletion of a 
single YAP1 allele in STK38-null mice impairs tumorigenesis in the colon when STK38L 
is also deleted. The findings of this study strongly suggest that STK38L has tumor 
suppressor function in the colon. However, it should be noted that STK38L-null mice are 
phenotypically normal [180]. These mice exhibit elevated STK38 protein levels in the 
colon, possibly to compensate for the loss of STK38L. Nevertheless, these mice fail to 
develop any discernable malignancies, suggesting that selective STK38L inhibition will 
be well tolerated. 
 The role of STK38L in cancer may ultimately be context-dependent. For example, 
in vivo studies have only observed STK38L tumor suppressor function in the absence of 
STK38 [179, 180]. Furthermore, several studies have suggested that STK38L promotes 
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tumorigenesis. Early work demonstrated that STK38L can induce the degradation of p21, 
an inducer of senescence, as well as stabilize c-Myc, a potent oncoprotein [236]. 
Additional studies have demonstrated that RNAi-mediated depletion of STK38L inhibits 
the proliferation of several colon cancer cell lines [266, 299]. We observed a similar 
effect in a subset of PDAC cell lines. However, this effect failed to generalize across the 
entire PDAC cell line panel, suggesting that STK38L is only essential for cell survival in 
certain contexts. We noted that PDAC cell lines sensitive to STK38L depletion expressed 
high STK38L protein levels. Additionally, high STK38L mRNA expression was 
correlated with decreased overall survival in PDAC patients. These observations strongly 
indicate that STK38L does not have tumor suppressor function in the context of PDAC. 
Our findings highlight context-dependent pro-tumorigenic roles for STK38L. In 
concordance with these findings, a recent study has demonstrated that STK38 promotes 
survival in HRAS-transformed cell lines by mediating clearance of damaged 
mitochondria [212]. However, STK38L does not compensate for loss of STK38 function 
in this context, indicating non-redundant function for these related kinases. Indeed, we 
found that STK38 expression levels do not affect cytotoxicity that is induced following 
STK38L depletion in PDAC cell lines. This observation suggests that the pro-
tumorigenic function of STK38L in PDAC is not shared with STK38 and, thus, provides 
further support for STK38L as a therapeutic target. 
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C. STK38L and KRAS Oncogene Dependency in PDAC 
 The pro-survival function of STK38L is closely related to KRAS oncogene 
dependency in PDAC cell lines. We observed highly significant correlations between 
STK38L and KRAS expression levels in PDAC cell lines as well as primary tumors. 
However, the mechanistic relationship between STK38L and KRAS remains unclear. 
STK38L depletion failed to induce consistent effects on downstream activation of KRAS 
effector pathways. Furthermore, expression of mutant forms of KRAS 4A and 4B 
isoforms does not change STK38L expression levels (Fig. 19). Therefore, we conclude 
that STK38L and KRAS function via independent pathways to promote tumor cell 
survival. Further characterization of the mechanistic relationship between STK38L and 
KRAS will be critical to fully understand context-dependent tumor cell survival signaling 
networks in KRAS-mutant PDACs. 
 
Figure 19. KRAS does not modulate STK38L expression. Western blot of BxPC3 cells 72 h post-
transduction with lentiviral expression vectors for GFP, KRAS 4A, or KRAS 4B. GAPDH serves as a gel 
loading control. 
 
D. STK38L Non-Oncogene Dependency in other KRAS-Mutant Cancers 
 STK38L non-oncogene dependency may also extend to other malignancies where 
KRAS mutations are prevalent, such as those of the colon and lung. Previous work 
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revealed that STK38L is overexpressed in KRAS-dependent colon cancer cell lines 
harboring KRAS mutations [266]. Furthermore, shRNA-mediated depletion of STK38L 
in one of these cell lines (SW620) inhibited cell proliferation. These findings are 
consistent with our observations in the context of PDAC. However, the effects of 
STK38L depletion on proliferation were tested in only one KRAS-dependent colon 
cancer cell line and should, therefore, be assessed in a larger cell line panel for validation. 
STK38L has not been studied in the context of lung cancer to date. Nevertheless, it is 
worth noting that the chromosome region 12p11-12, which contains the STK38L and 
KRAS genes, is amplified in a fraction of lung and colon cancers [269, 270]. Recurrent 
amplification of a particular gene in the context of cancer often occurs as a consequence 
of a selective pressure that renders tumor cells dependent on the expression of that gene 
for continued proliferation and/or survival. Our study failed to establish a correlation 
between STK38L gene copy number and STK38L dependency in PDAC. However, this 
result does not rule out the existence of such a relationship in lung and/or colon cancer. 
Regardless, further study of STK38L dependency in other KRAS-mutant cancers should 
be carried out to assess whether STK38L poses a potential therapeutic vulnerability in 
contexts other than PDAC. 
 
E. Mechanisms Underlying the Pro-Survival Function of STK38L 
 Mechanistically, we demonstrate for the first time that STK38L depletion causes 
cell death, in part, via induction of LATS2 protein expression. LATS2 is a well-
established tumor suppressor that, under normal physiological conditions, can restrict cell 
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proliferation and promote apoptotic cell death. The mechanisms underlying LATS2-
mediated cytotoxicity in PDAC cell lines have yet to be fully determined, but could 
involve perturbations in the phosphorylation and function of NDR/LATS substrates p21 
and YAP [151, 185, 191, 211, 297]. YAP can be constitutively-activated in PDAC, and 
genetic ablation of YAP1 limits KRAS-driven PDAC progression in mouse models [102]. 
Thus, the role of the STK38L-LATS2 axis in regulation of YAP will be interesting to 
investigate in future studies. 
 Although the mechanism by which STK38L depletion induces LATS2 expression 
has not been fully elucidated, our findings suggest it could be related to STK38L-
mediated regulation of YAP. In a previous study, STK38L was shown to phosphorylate 
YAP at multiple sites [191]. This activity results in the cytoplasmic retention and 
subsequent degradation of YAP. Additional work revealed that LATS2 is a transcriptional 
target of YAP and TAZ [296]. Taken together, these findings suggest that STK38L 
depletion promotes YAP nuclear localization and results in the induction of LATS2 
expression. Consequently, LATS2 would restrict cellular proliferation and/or induce 
apoptosis by phosphorylating, and promoting the degradation of, YAP as well as TAZ. 
This proposed mechanism suggests that STK38L and LATS2 exert opposing effects on 
cellular viability by directly phosphorylating YAP. However, these seemingly 
contradictory outcomes are likely due to a lack of functional redundancy between 
STK38L and LATS2. In one study, overexpression of STK38L failed result in the same 
phospho-shift of YAP observed in response to LATS2 overexpression [185]. Subsequent 
work revealed that STK38L phosphorylates YAP at S61, S109, S127, and S164 [191]. 
  
101
However, STK38L cannot phosphorylate YAP at S381, which is required for YAP 
degradation. LATS2 is capable of phosphorylating YAP at all five aforementioned sites 
[194]. Thus, STK38L may function to “fine-tune” YAP subcellular localization, whereas 
LATS2 robustly induces the degradation of YAP and TAZ (Fig. 20). These parallel, yet 
nonequivalent activities, would allow for STK38L to promote cell survival while LATS2 
exerts the opposite effect. 
 
Figure 20. Proposed mechanism for STK38L-mediated suppression of LATS2 expression. STK38L 
sequesters YAP in the in the cytoplasm, suppressing LATS2 expression and promoting cell survival (left 
panel). STK38L depletion results in YAP nuclear localization and promotes YAP/TEAD-mediated 
induction of LATS2 expression (middle panel). Over time, LATS2 accumulation promotes the degradation 
of YAP/TAZ, resulting in the loss of cell viability (right panel). 
 Although the induction of LATS2 expression is partially responsible for the 
antiproliferative effect of STK38L depletion, our findings suggest that STK38L promotes 
cell survival and proliferation via one or more additional mechanisms. Previous studies 
suggested that STK38L might promote tumorigenesis by directly phosphorylating p21, 
resulting in the subsequent degradation of the cyclin-dependent kinase inhibitor [151, 
211]. Consistent with this work, we observed increased p21 protein levels following 
STK38L depletion in six of eight PDAC cell lines. This effect did not appear to associate 
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exclusively with STK38L dependency. Furthermore, the combined depletion of STK38L 
and p21 failed to rescue the viability and proliferation defects observed following 
STK38L depletion alone. Thus, it is unlikely that the pro-survival function of STK38L is 
related to the regulation of p21 protein stability. 
 Previous work has also suggested that STK38L can promote tumorigenesis by 
stabilizing the transcription factor c-Myc, a potent oncoprotein that is frequently 
deregulated in a number of cancers [151]. However, this function is not associated with 
the kinase activity of STK38L. Rather, the stabilization of c-Myc results from a direct 
binding interaction with STK38L, whereby STK38L prevents c-Myc from being 
ubiquitinated and subsequently degraded. Our findings suggest that the pro-survival 
function of STK38L is kinase activity-dependent. Nevertheless, we examined the effects 
of STK38L depletion on c-Myc protein levels but failed to observe consistent effects 
across the PDAC cell line panel. Therefore, we conclude that the pro-survival survival 
function of STK38L is unrelated to c-Myc protein stability. 
 Further study is required to identify the additional mechanisms by which STK38L 
might promote cell survival and proliferation. Our study focused on known STK38L-
interacting proteins and KRAS-associated pathways. However, an unbiased approach 
may ultimately prove more effective at identifying novel mechanisms underlying the pro-
survival function of STK38L. Therefore, future studies should analyze changes in global 
gene expression following modulation of STK38L expression/activity. This approach will 
allow for the identification of cellular pathways or processes regulated by the kinase. 
Additionally, immunoprecipitation-mass spectroscopy should be carried out in parallel to 
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identify STK38L-interacting proteins. Collectively, these approaches will provide insight 
into how STK38L promotes cell survival and proliferation in the context of PDAC.  
 
F. Developing a Biomarker of STK38L Non-Oncogene Dependency 
 To develop STK38L kinase inhibition as a therapeutic strategy, it will be 
necessary to identify additional biomarkers of STK38L dependency. Our analysis of 
twelve PDAC cell lines demonstrated that STK38L gene copy number does not predict 
STK38L dependency. However, this analysis of STK38L gene copy number was 
performed using a qPCR-based approach, which has inherent limitations. Future studies 
of STK38L amplification will utilize fluorescence in situ hybridization (FISH) to 
definitively quantitate STK38L gene copy number gain in cell lines and primary tumors 
and determine its utility as a biomarker. STK38L mRNA or protein expression levels may 
provide a more accurate biomarker for prediction of STK38L dependency in tumors. 
However, it may be necessary to identify additional biomarkers of STK38L dependency, 
such as co-occurring genetic alterations or gene expression signatures. 
 
G. Concluding Remarks 
 Our findings highlight an important context-dependent role for STK38L kinase 
activity in promoting the survival of a distinct subset of KRAS-dependent PDAC cell 
lines via suppression of LATS2 apoptotic function. The STK38L survival signaling axis 
represents an important vulnerability in a subset of PDAC cases that can potentially be 
exploited for therapeutic benefit. In future studies, it will be important to develop ATP 
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competitive inhibitors to validate the kinase-dependent functions of STK38L in normal 
cells and in driving the survival of STK38L-dependent PDAC cells. These inhibitors will 
also allow for further characterization of STK38L in the contexts of normal physiology as 
well as disease. 
 Our study of STK38L dependency in PDAC illustrates the challenges associated 
with identifying novel therapeutic targets for treatment of the disease. Oncogenic KRAS 
mutations are crucial in the development of PDAC. However, attempts to develop agents 
directed against KRAS have been unsuccessful to date. Furthermore, such therapeutics 
are unlikely to be universally efficacious, as studies utilizing PDAC cell lines and 
GEMMs have demonstrated that KRAS is dispensable in a number of contexts. The lack 
of additional high-frequency genetic alterations, beyond the loss of a few tumor 
suppressor genes, suggests that the development of broadly efficacious therapeutic agents 
to treat PDAC is unlikely. The heterogeneous nature of the disease provides further 
support for this notion. Ultimately, precision medicine will be needed to effectively treat 
PDAC. Genomic analyses have revealed that myriad low-frequency alterations are 
associated with well-defined subsets of PDAC. However, the context-dependent 
contributions of these alterations to PDAC pathogenesis are unclear. Additionally, gene 
copy number gains and increased mRNA expression are not always predictive of gene 
dependency, as we have demonstrated with STK38L. Further characterization of PDAC, 
with an increased emphasis on identifying gene expression signatures and alterations in 
protein expression that are associated with subsets of tumors, will be necessary to identify 
potential therapeutic vulnerabilities. The development of subtype-selective therapeutics 
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poses a daunting challenge. Nevertheless, this approach has the greatest potential to 
dramatically improve the prognosis of PDAC patients. 
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